{"gene":"PSMB5","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":1997,"finding":"Radiolabeling of 20S and 26S proteasomes with active-site-directed peptidyl chloromethane and diazomethane inhibitors showed that the MB1 subunit (PSMB5) is one of the catalytic components associated with chymotrypsin-like and trypsin-like peptidase activities; incorporation of label into PSMB5 was blocked by prior treatment with calpain inhibitor or 3,4-dichloroisocoumarin, confirming active-site involvement.","method":"Radiolabeled active-site inhibitor labeling, 2D-PAGE, HPLC, immunoblotting with subunit-specific antibodies","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro active-site labeling with multiple inhibitors and orthogonal separation methods","pmids":["9312091"],"is_preprint":false},{"year":1996,"finding":"The 20S proteasome β5 subunit (PSMB5/MB1) harbors a threonine-based active site and contributes to the chymotrypsin-like peptidase activity of the multicatalytic protease complex; the 26S proteasome (formed by association of 20S with the 19S regulatory complex) degrades ubiquitinated proteins in an ATP-dependent manner.","method":"Biochemical purification, kinetic analysis, active-site characterization (review synthesizing multiple labs' reconstitution and inhibitor studies)","journal":"Annual Review of Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple independent labs, reconstitution and active-site mutagenesis, widely replicated","pmids":["8811196"],"is_preprint":false},{"year":1997,"finding":"The mouse Psmb5 gene encoding the constitutively expressed β5 proteasome subunit is composed of three exons spanning ~5 kb, with a unique exon-intron organization radically different from its paralog Lmp7 (PSMB8), suggesting distinct evolutionary history; upon IFN-γ stimulation, PSMB5 is displaced from the 20S proteasome by LMP7, altering cleavage specificity to facilitate MHC class I antigen presentation.","method":"Genomic cloning, sequencing, interspecific backcross mapping, fluorescence in situ hybridization","journal":"Immunogenetics","confidence":"Medium","confidence_rationale":"Tier 2 — genetic and structural characterization, functional inference from IFN-γ displacement well established by prior work","pmids":["9382924"],"is_preprint":false},{"year":2006,"finding":"PSMB5 expression is transcriptionally induced by the bifunctional enzyme inducer 3-methylcholanthrene through the Nrf2-ARE pathway but not through the AhR/Arnt-XRE pathway; mutation of the proximal AREs in the Psmb5 promoter abolished inducibility, and 3-MC failed to induce PSMB5 in nrf2-null cells.","method":"Luciferase reporter assay with ARE/XRE deletion/mutation constructs, overexpression of AhR/Arnt, nrf2-null cell comparison, nuclear Nrf2 level measurement","journal":"Biochemical and Biophysical Research Communications","confidence":"High","confidence_rationale":"Tier 1–2 — promoter mutagenesis plus genetic null cell validation, multiple orthogonal approaches in one study","pmids":["16723119"],"is_preprint":false},{"year":2008,"finding":"Acquired bortezomib resistance in THP1 myelomonocytic cells is associated with (1) an Ala49Thr point mutation in the bortezomib-binding pocket of PSMB5 and (2) selective overexpression of PSMB5 protein up to 60-fold without comparable upregulation of other proteasome subunits; siRNA-mediated silencing of PSMB5 restored bortezomib sensitivity, confirming PSMB5 as the direct resistance determinant.","method":"DNA sequencing, Western blot, siRNA knockdown, cytotoxicity assays, chymotrypsin-like activity assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — mutation identification + siRNA rescue + activity assay, multiple orthogonal methods, widely replicated","pmids":["18565852"],"is_preprint":false},{"year":2008,"finding":"Overexpression and gene amplification of PSMB5 (demonstrated by FISH) in bortezomib-resistant Jurkat T-lymphoblastic leukemia cells increases chymotrypsin-like proteasome activity and correlates with upregulated NF-κB activity after bortezomib treatment, suggesting PSMB5 amplification-driven resistance operates through sustained NF-κB pathway.","method":"RT-qPCR, in situ hybridization/FISH, fluorometric chymotrypsin-like activity assay, Western blot for IκB-α and P-gp","journal":"Experimental Hematology","confidence":"Medium","confidence_rationale":"Tier 2 — gene amplification confirmed by FISH + functional activity assay, single lab","pmids":["18562081"],"is_preprint":false},{"year":2009,"finding":"Three distinct PSMB5 mutations (G322A→Ala49Thr, C323T→Ala49Val, and compound G322A+C326T→Ala49Thr+Ala50Val) confer graded levels of bortezomib resistance (22-, 39-, and 67-fold, respectively) in Jurkat cells; resistance correlates with reduced inhibition of chymotrypsin-like activity by bortezomib, establishing that amino acids 49 and 50 of PSMB5 are critical for bortezomib binding.","method":"cDNA sequencing, limited dilution cloning, cytotoxicity assays, fluorometric chymotrypsin-like activity assay","journal":"Experimental Hematology","confidence":"High","confidence_rationale":"Tier 2 — multiple independent point mutations with quantitative resistance/activity data, mechanistically informative structure-function relationship","pmids":["19426847"],"is_preprint":false},{"year":2010,"finding":"A G322A point mutation in PSMB5 in bortezomib-resistant myeloma cell lines causes conformational changes in the bortezomib-binding pocket, reducing accumulation of polyubiquitinated proteins and preventing catastrophic ER stress/CHOP induction; transfection of mutant PSMB5 into parental cells recapitulated reduced bortezomib-induced apoptosis, directly linking the PSMB5 mutation to ER stress avoidance.","method":"DNA sequencing, transfection of wild-type vs. mutant PSMB5, Western blot for polyubiquitinated proteins and CHOP, caspase/BH3-only protein analysis","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 — direct rescue/overexpression experiment linking specific mutation to mechanistic phenotype, multiple readouts","pmids":["20555361"],"is_preprint":false},{"year":2010,"finding":"Inhibition of Gα12/13 signaling downregulates PSMB5 expression at the mRNA and protein levels, enhances bortezomib-mediated cytotoxicity, and reduces chymotrypsin-like proteasome activity; active Gα12QL or Gα13QL reversed these effects, placing Gα12/13 upstream of PSMB5 regulation.","method":"RT-PCR, Western blot, proteasome activity assay, transfection with active mutants and minigene constructs, cytotoxicity assay","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 — bidirectional genetic manipulation (gain and loss of function) with functional readouts, single lab","pmids":["20478922"],"is_preprint":false},{"year":2012,"finding":"PSMB5 mutations (identified in bortezomib-resistant THP1 sublines) confer marked cross-resistance to second-generation proteasome inhibitors carfilzomib, ONX0912, and ONX0914, though less pronounced than to bortezomib; P-glycoprotein overexpression provides an independent resistance mechanism by reducing effective intracellular drug concentration, and Pgp inhibition with reversin 121 restores parental sensitivity.","method":"Cytotoxicity assays, β5 subunit chymotrypsin-like activity assay, flow cytometry for Pgp, Pgp inhibitor reversal experiments","journal":"The Journal of Pharmacology and Experimental Therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 — functional activity assays across multiple inhibitors + pharmacological reversal, single lab","pmids":["22235146"],"is_preprint":false},{"year":2014,"finding":"STAT3 transcriptionally activates PSMB5 expression; knockdown of STAT3 decreases PSMB5 mRNA and protein, inhibition of phospho-STAT3 reduces PSMB5 in constitutively active-STAT3 cells, and accumulation of active STAT3 induces PSMB5 promoter activity. EGF-induced upregulation of β subunits including PSMB5 was blocked by EGFR or STAT3 inhibition but not by PI3K/AKT or MEK/ERK inhibition.","method":"STAT3 knockdown, constitutively active STAT3 overexpression, luciferase promoter assay, Western blot, RT-PCR, pathway inhibitor panel","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — bidirectional STAT3 manipulation + promoter assay + pathway specificity analysis, multiple orthogonal methods","pmids":["24627483"],"is_preprint":false},{"year":2014,"finding":"Overexpression of PSMB5 in late-stage senescent human bone marrow stromal cells restores 20S proteasome activity and promotes cell growth potentially via upregulating the Cyclin D1/CDK4 complex; conversely, PSMB5 knockdown in early-stage cells reduces proteasome activity and proliferation, mimicking a senescent phenotype. PSMB5 overexpression also enhances cell survival under oxidative stress and preserves pluripotency.","method":"PSMB5 overexpression and siRNA knockdown, proteasome activity assay, BrdU/proliferation assay, Western blot for Cyclin D1/CDK4, H2O2 survival assay, neural differentiation assay","journal":"Biochemical and Biophysical Research Communications","confidence":"High","confidence_rationale":"Tier 2 — bidirectional manipulation with multiple functional readouts, mechanistic link to Cyclin D1/CDK4","pmids":["24393841"],"is_preprint":false},{"year":2017,"finding":"High expression of PSMB5 promotes M2 macrophage polarization and suppresses M1 differentiation; PSMB5 knockdown in THP-1 monocytes shifts differentiation toward M1 macrophages. PSMB5 knockdown in MDA-MB-231 breast cancer cells inhibits cell growth and migration. In vivo lentiviral PSMB5 shRNA delivery significantly reduced tumor growth in a subcutaneous mouse model.","method":"shRNA knockdown, colony formation assay, Boyden chamber migration assay, monocyte differentiation assay, in vivo subcutaneous tumor model","journal":"American Journal of Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with defined cellular phenotypes in vitro and in vivo, single lab","pmids":["29218236"],"is_preprint":false},{"year":2017,"finding":"20-HETE regulates PSMB5 expression in a tissue-specific manner through the TGF-β/Smad3 signaling pathway; Smad3 directly binds the Smad binding element (SBE) in the Psmb5 promoter as demonstrated by EMSA, and the TGF-β receptor I kinase inhibitor SB431542 reverses 20-HETE-induced changes in PSMB5 levels.","method":"Luciferase reporter assay, EMSA, TGF-β pathway inhibitor (SB431542), Western blot for TGF-β1, Smad3 phosphorylation, and PSMB5","journal":"Prostaglandins & Other Lipid Mediators","confidence":"Medium","confidence_rationale":"Tier 1–2 — EMSA demonstrates direct Smad3-SBE interaction + promoter reporter + pharmacological validation, single lab","pmids":["28807746"],"is_preprint":false},{"year":2019,"finding":"PSMB5 is a direct target of miR-127-3p; overexpression of miR-127-3p reduces PSMB5 protein and inhibits prostate cancer cell invasion and migration. CTCF transcription factor suppresses miR-127-3p expression by binding the miR-127-3p promoter, thereby indirectly upregulating PSMB5 to promote bone metastasis.","method":"Luciferase 3'UTR reporter assay, miR-127-3p overexpression, CTCF ChIP or promoter binding assay, invasion/migration assay","journal":"FEBS Letters","confidence":"Medium","confidence_rationale":"Tier 2 — direct miRNA target validation with reporter assay + upstream CTCF mechanism, single lab","pmids":["31562641"],"is_preprint":false},{"year":2019,"finding":"Ilexgenin A (IA) increases PSMB5 expression in an Nrf2-dependent manner in endothelial cells; Nrf2 knockdown abolishes IA-induced PSMB5 upregulation. Increased PSMB5 activity promotes proteasomal degradation of Drp1, thereby suppressing mitochondrial fission and improving endothelial function. Proteasome inhibitor epoxomicin blocked IA's effect on Drp1 expression, confirming the PSMB5-mediated degradation mechanism.","method":"Nrf2 siRNA knockdown, Western blot for PSMB5 and Drp1, proteasome inhibitor (epoxomicin) treatment, mitochondrial morphology assessment","journal":"Drug Development Research","confidence":"Medium","confidence_rationale":"Tier 2 — genetic (siRNA) and pharmacological (epoxomicin) validation of Nrf2→PSMB5→Drp1 axis, single lab","pmids":["30762899"],"is_preprint":false},{"year":2020,"finding":"Curcumin elevates miR-142-3p expression by inhibiting histone acetyltransferase p300, and miR-142-3p directly targets the PSMB5 3'UTR to reduce PSMB5 protein levels and chymotrypsin-like activity of the 20S proteasome; loss of p300 and PSMB5 each independently reduced cell proliferation in triple-negative breast cancer cells.","method":"miR-142-3p mimic/inhibitor, PSMB5 3'UTR luciferase reporter, p300 overexpression, fluorometric proteasome activity assay, BrdU proliferation assay, in vivo xenograft","journal":"Phytomedicine","confidence":"High","confidence_rationale":"Tier 1–2 — direct 3'UTR targeting validated by reporter + upstream p300 mechanism + in vivo confirmation, multiple orthogonal methods","pmids":["32866906"],"is_preprint":false},{"year":2021,"finding":"EGCG activates PSMB5 (20S proteasome β5, chymotrypsin-like activity) and may directly interact with PSMB5; activated PSMB5 is required for EGCG-induced upregulation of Nmnat2 protein expression. Nmnat2 subsequently activates SIRT6 histone deacetylase, which blocks NF-κB DNA binding activity induced by angiotensin II, thereby inhibiting cardiac hypertrophy. PSMB5 knockdown attenuated EGCG's anti-hypertrophic effects.","method":"RNA interference (PSMB5 knockdown), luciferase reporter for NF-κB, EMSA for NF-κB DNA binding, fluorometric SIRT6 activity assay, Western blot, in vivo aortic constriction model","journal":"Acta Physiologica","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knockdown confirms PSMB5 requirement in pathway, multiple downstream readouts, single lab","pmids":["33315278"],"is_preprint":false},{"year":2021,"finding":"rHMGB1 promotes mitochondrial fusion in endothelial cells via the CXCR4/PSMB5 pathway: rHMGB1 increases PSMB5 expression through CXCR4 (not TLR4, RAGE, or TLR2), and PSMB5 mediates proteasomal degradation of Drp1, reducing mitochondrial fission. Inhibition of PSMB5 with epoxomicin abolished rHMGB1-induced Drp1 downregulation and mitochondrial fusion, independent of NRF2.","method":"Specific receptor inhibitors (AMD3100/CXCR4, C29/TLR2, TAK-242/TLR4, FPS-ZM1/RAGE), epoxomicin (PSMB5 inhibitor), NRF2 siRNA, confocal/TEM mitochondrial morphology, Western blot","journal":"Oxidative Medicine and Cellular Longevity","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological and genetic dissection of receptor-PSMB5-Drp1 axis, single lab","pmids":["34394840"],"is_preprint":false},{"year":2022,"finding":"PSMB5 knockdown suppresses CGG repeat-associated neurodegeneration in both Drosophila FXTAS models and N2A cells; the PSMB5 expression QTL variant rs11543947-A is associated with decreased PSMB5 expression and delayed FXTAS onset in human FMR1 premutation carriers. PSMB5 knockdown reduces toxicity via both RAN translation and RNA-mediated mechanisms.","method":"Drosophila genetic screen (whole-genome sequencing + candidate knockdown), N2A cell knockdown, human genetic association (QTL analysis), RAN translation and RNA toxicity assays","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 — cross-species epistasis (fly + mammalian cell) with human genetic validation, multiple mechanism dissection","pmids":["35617426"],"is_preprint":false},{"year":2022,"finding":"ISG20L2 competes directly with PSMB5 for bortezomib binding: biotinylated bortezomib pull-down showed ISG20L2 competes with PSMB5 for drug binding, and surface plasmon resonance confirmed direct bortezomib-ISG20L2 interaction. In ISG20L2-high myeloma cells, ISG20L2 attenuates bortezomib binding to PSMB5, reducing proteasome inhibition and cell death.","method":"Biotinylated bortezomib pull-down assay, surface plasmon resonance, gain/loss-of-function in vitro and in vivo experiments, proteasome activity assay","journal":"JCI Insight","confidence":"High","confidence_rationale":"Tier 1 — direct binding competition demonstrated by two orthogonal biochemical methods (pull-down + SPR)","pmids":["36040812"],"is_preprint":false},{"year":2022,"finding":"PSMB5 overexpression in intestinal epithelial cells reduces LPS-induced NLRP3 inflammasome activation and pyroptosis by decreasing intracellular ROS generation; ROS scavenger NAC mimicked this protective effect, placing PSMB5 upstream of ROS-dependent NLRP3 activation in a model of ulcerative colitis.","method":"PSMB5 overexpression, NLRP3/caspase-1/ASC Western blot, LDH release assay, ROS measurement, NAC/Z-VAD-FMK/MCC950 pharmacological dissection, in vivo DSS colitis model","journal":"Disease Markers","confidence":"Medium","confidence_rationale":"Tier 2 — overexpression + multiple pathway inhibitors establish mechanistic order, single lab","pmids":["36061354"],"is_preprint":false},{"year":2024,"finding":"In rheumatoid arthritis T cells, elevated mitochondrial succinyl-CoA causes succinylation of BRD2 transcription factor, which impairs BRD2-dependent transcription of PSMB5; reduced PSMB5 leads to accumulation of the transcription factor Hobit, promoting CD4+ T cell differentiation into tissue-resident memory (Trm) cells and synovial inflammation. ChIP-qPCR validated direct BRD2 binding to the PSMB5 promoter.","method":"BRD2 chromatin immunoprecipitation-qPCR, Hobit knockdown, succinyl-CoA manipulation, humanized NSG chimera model, Trm differentiation assay","journal":"Arthritis & Rheumatology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-qPCR validates direct BRD2-PSMB5 promoter interaction + in vivo model, single lab","pmids":["39037181"],"is_preprint":false},{"year":2025,"finding":"The transcription factor THAP1 (DYT6 dystonia gene) directly regulates PSMB5 gene expression to maintain basal proteasome activity; loss of THAP1 reduces PSMB5 levels, disrupts proteasome assembly, impairs proteostasis, and causes cell death. Exogenous PSMB5 expression rescues THAP1-deficient cell toxicity. A deep mutational scan of THAP1 variants correlated with PSMB5 regulatory capacity.","method":"Genome-wide CRISPR genetic screen (DepMap coessentiality), THAP1 knockout, PSMB5 exogenous rescue, proteasome assembly assay, ubiquitinated protein accumulation, RNA-seq, deep mutational scan","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 1–2 — genome-wide screen + genetic rescue + proteasome assembly readout + deep mutational scan, multiple orthogonal methods","pmids":["39929834","39952963"],"is_preprint":false},{"year":2025,"finding":"Complementary study confirms THAP1 transcriptionally activates PSMB5; THAP1 depletion decreases PSMB5 mRNA and protein, disrupts proteasome assembly, and increases ubiquitinated protein accumulation. These findings identify THAP1 as a critical regulator of proteasome function and suggest proteasome dysfunction contributes to DYT6 dystonia pathogenesis.","method":"THAP1 knockout/knockdown, Western blot, proteasome activity assay, ubiquitinated protein accumulation, RNA-seq transcriptional target definition","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 2 — independently replicated across two contemporaneous papers using complementary approaches","pmids":["39952963","39929834"],"is_preprint":false}],"current_model":"PSMB5 encodes the β5 catalytic subunit of the 20S proteasome with a threonine-based active site responsible for chymotrypsin-like peptidase activity; its expression is transcriptionally controlled by THAP1 (basal), Nrf2-ARE (stress-induced), STAT3, Gα12/13, TGF-β/Smad3, BRD2, and miRNAs including miR-142-3p and miR-127-3p; it is displaced by the IFN-γ-inducible paralog LMP7 to remodel proteasome specificity for antigen presentation; bortezomib binds directly in the PSMB5 active-site pocket (residues Ala49/Ala50 are critical), and point mutations at these residues or PSMB5 overexpression confer bortezomib resistance by reducing drug binding and preventing ER stress; ISG20L2 can additionally compete with PSMB5 for bortezomib; beyond proteolysis, PSMB5-mediated degradation of Drp1 suppresses mitochondrial fission, and PSMB5 activity modulates ROS levels, NLRP3 inflammasome activation, Hobit-driven T cell differentiation, and Nmnat2/SIRT6/NF-κB signaling in cardiac hypertrophy."},"narrative":{"teleology":[{"year":1996,"claim":"Identification of PSMB5 as a catalytic subunit of the 20S proteasome with a threonine-based active site responsible for chymotrypsin-like activity resolved the longstanding question of which subunits harbor the proteolytic centers of the multicatalytic protease.","evidence":"Biochemical purification, kinetic analysis, and active-site characterization synthesized across multiple labs","pmids":["8811196"],"confidence":"High","gaps":["Crystal structure of human PSMB5 in the 20S context was not yet available","Relative contribution of β5 versus β1/β2 to overall proteasomal flux was not quantified"]},{"year":1997,"claim":"Active-site-directed inhibitor labeling confirmed that PSMB5 is one of the catalytically active subunits and established that IFN-γ-induced LMP7 displaces PSMB5, fundamentally altering proteasome cleavage specificity for immune function.","evidence":"Radiolabeled peptidyl inhibitor labeling with 2D-PAGE/HPLC of purified 20S/26S proteasomes; genomic cloning showing distinct evolutionary origin of PSMB5 vs. LMP7","pmids":["9312091","9382924"],"confidence":"High","gaps":["Mechanism governing selective incorporation of LMP7 versus PSMB5 into assembling proteasomes was unresolved","In vivo antigen repertoire consequences of β5↔LMP7 exchange not directly measured"]},{"year":2006,"claim":"Discovery that Nrf2-ARE elements in the PSMB5 promoter mediate stress-responsive transcriptional induction established the first defined pathway linking oxidative stress sensing to proteasome subunit upregulation.","evidence":"Promoter-reporter mutagenesis of AREs plus validation in nrf2-null cells","pmids":["16723119"],"confidence":"High","gaps":["Whether Nrf2 coordinately induces all catalytic β subunits or selectively PSMB5 was unclear","Physiological stimuli beyond 3-methylcholanthrene activating this axis were not tested"]},{"year":2008,"claim":"Identification of the Ala49Thr mutation in the bortezomib-binding pocket of PSMB5 — combined with up to 60-fold PSMB5 overexpression — as the molecular basis of acquired bortezomib resistance resolved a critical question for proteasome inhibitor pharmacology.","evidence":"DNA sequencing, siRNA rescue of sensitivity, and chymotrypsin-like activity assay in THP1 and Jurkat resistant lines; FISH-confirmed gene amplification","pmids":["18565852","18562081"],"confidence":"High","gaps":["Whether PSMB5 mutations occur in clinical bortezomib-refractory patients at appreciable frequency was unknown","Structural basis of how Ala49 mutations alter the binding pocket was modeled but not crystallographically resolved"]},{"year":2009,"claim":"Systematic mutagenesis at Ala49 and Ala50 established a quantitative structure–resistance relationship, demonstrating that both residues form the critical bortezomib-docking contacts and that double mutations confer >60-fold resistance.","evidence":"Multiple independent PSMB5 point mutations (Ala49Thr, Ala49Val, Ala49Thr+Ala50Val) with graded cytotoxicity and activity data in Jurkat clones","pmids":["19426847"],"confidence":"High","gaps":["Cross-resistance profile to next-generation inhibitors had not yet been evaluated","Impact of these mutations on substrate specificity beyond drug binding was not assessed"]},{"year":2010,"claim":"The mechanistic link between PSMB5 mutations and drug resistance was completed by showing that mutant PSMB5 prevents bortezomib-induced accumulation of polyubiquitinated proteins and catastrophic ER stress/CHOP induction, while Gα12/13 signaling was identified as an upstream transcriptional regulator of PSMB5.","evidence":"Transfection of mutant vs. wild-type PSMB5 with ER stress readouts; bidirectional Gα12/13 manipulation with proteasome activity assays","pmids":["20555361","20478922"],"confidence":"High","gaps":["Whether Gα12/13 acts through Nrf2, STAT3, or an independent transcription factor on the PSMB5 promoter was unresolved","In vivo relevance of Gα12/13-PSMB5 axis in tumor drug response was untested"]},{"year":2012,"claim":"PSMB5 mutations were shown to confer cross-resistance to carfilzomib and related next-generation proteasome inhibitors, indicating the binding pocket alterations are not bortezomib-specific; P-glycoprotein overexpression was identified as an independent co-resistance mechanism.","evidence":"Multi-inhibitor cytotoxicity and activity assays with Pgp inhibitor reversal in THP1 resistant sublines","pmids":["22235146"],"confidence":"Medium","gaps":["Relative clinical prevalence of PSMB5 mutation versus Pgp-mediated resistance was unknown","Whether newer epoxyketone inhibitors fully bypass Ala49/50 mutations required structural studies"]},{"year":2014,"claim":"STAT3 was established as a direct transcriptional activator of PSMB5 via the EGF-EGFR axis, adding a growth-factor-driven regulatory input, while PSMB5 overexpression was shown to restore proteasome activity and proliferation in senescent stromal cells via Cyclin D1/CDK4.","evidence":"Bidirectional STAT3 manipulation with promoter-reporter assays; PSMB5 gain/loss-of-function in senescent bone marrow stromal cells with proliferation and survival readouts","pmids":["24627483","24393841"],"confidence":"High","gaps":["Whether STAT3 and Nrf2 act on overlapping or distinct PSMB5 promoter elements was not determined","Cyclin D1 as a direct PSMB5-degraded substrate versus indirect effect was unclear"]},{"year":2017,"claim":"TGF-β/Smad3 was shown to directly bind the PSMB5 promoter via an SBE, adding a tissue-context-dependent transcriptional input, while PSMB5 knockdown in breast cancer cells inhibited growth, migration, and M2 macrophage polarization, broadening PSMB5's biological roles beyond proteolysis per se.","evidence":"EMSA for Smad3-SBE binding plus TGF-βRI inhibitor; shRNA in MDA-MB-231 with in vivo tumor model and THP-1 macrophage differentiation assays","pmids":["28807746","29218236"],"confidence":"Medium","gaps":["Substrates whose degradation mediates the M1/M2 polarization shift were not identified","Tissue-specific integration of multiple transcription factors on the PSMB5 promoter lacked a unified model"]},{"year":2019,"claim":"Two miRNAs — miR-127-3p and miR-142-3p — were validated as direct post-transcriptional repressors of PSMB5 via 3ʹ-UTR targeting, establishing that PSMB5 levels are tuned by both transcriptional and post-transcriptional mechanisms; PSMB5-mediated degradation of Drp1 was identified as a specific substrate-level mechanism suppressing mitochondrial fission.","evidence":"3ʹ-UTR luciferase reporters for both miRNAs; CTCF-miR-127-3p axis in prostate cancer; Nrf2 siRNA plus epoxomicin blockade confirming PSMB5→Drp1 degradation in endothelial cells","pmids":["31562641","32866906","30762899"],"confidence":"Medium","gaps":["Whether Drp1 is directly ubiquitinated for PSMB5-mediated degradation or indirectly stabilized was unresolved","Quantitative impact of miRNA regulation on steady-state proteasome pools in vivo was not measured"]},{"year":2021,"claim":"PSMB5 was positioned upstream of an Nmnat2→SIRT6→NF-κB cardioprotective axis, and an HMGB1/CXCR4 pathway was shown to signal through PSMB5 to degrade Drp1 independently of Nrf2, expanding the upstream receptor inputs that converge on PSMB5-dependent proteostasis.","evidence":"PSMB5 knockdown attenuating EGCG anti-hypertrophic effects with NF-κB EMSA/reporter; receptor-specific inhibitors (AMD3100) and epoxomicin dissecting HMGB1→CXCR4→PSMB5→Drp1 axis","pmids":["33315278","34394840"],"confidence":"Medium","gaps":["Direct physical interaction between CXCR4 signaling intermediates and PSMB5 promoter elements was not demonstrated","Whether PSMB5 directly stabilizes Nmnat2 or prevents its degradation was ambiguous"]},{"year":2022,"claim":"ISG20L2 was identified as a direct competitor of PSMB5 for bortezomib binding, revealing a novel resistance mechanism independent of PSMB5 mutation; simultaneously, PSMB5 overexpression was shown to suppress NLRP3 inflammasome activation via ROS reduction, and reduced PSMB5 expression was linked to CGG repeat-associated neurodegeneration in FXTAS models.","evidence":"Biotinylated bortezomib pull-down plus SPR for ISG20L2; PSMB5 overexpression with NLRP3/ROS readouts in DSS colitis model; cross-species PSMB5 knockdown in Drosophila FXTAS plus human eQTL association","pmids":["36040812","36061354","35617426"],"confidence":"High","gaps":["Structural basis of ISG20L2-bortezomib interaction was not resolved","Whether PSMB5's ROS-modulating effect is direct or secondary to altered proteostasis was unclear","Mechanism by which reduced PSMB5 alleviates CGG repeat toxicity (RAN translation vs. RNA-mediated) was not fully disentangled"]},{"year":2024,"claim":"BRD2 was identified as a direct transcriptional activator of PSMB5 by ChIP-qPCR, and metabolic succinylation of BRD2 in rheumatoid arthritis T cells impairs PSMB5 transcription, leading to Hobit accumulation and tissue-resident memory T cell differentiation — linking proteasome dysfunction to autoimmune pathology.","evidence":"BRD2 ChIP-qPCR at PSMB5 promoter, succinyl-CoA manipulation, Hobit knockdown rescue, humanized NSG chimera model","pmids":["39037181"],"confidence":"Medium","gaps":["Whether Hobit is a direct PSMB5 degradation substrate or accumulates indirectly was not established","Generalizability of succinylation-BRD2-PSMB5 axis beyond RA T cells was untested"]},{"year":2025,"claim":"Two independent studies established THAP1 as the critical basal transcriptional regulator of PSMB5, demonstrating that THAP1 loss reduces PSMB5 expression, disrupts proteasome assembly, impairs proteostasis, and causes cell death — rescued by exogenous PSMB5 — implicating proteasome dysfunction in DYT6 dystonia pathogenesis.","evidence":"Genome-wide CRISPR coessentiality screen, THAP1 knockout with PSMB5 rescue, proteasome assembly assays, deep mutational scan of THAP1 variants correlated with PSMB5 regulatory capacity","pmids":["39929834","39952963"],"confidence":"High","gaps":["Direct THAP1 binding site(s) on the PSMB5 promoter were not mapped at base-pair resolution in these studies","Whether THAP1-PSMB5 dysregulation is the primary driver of DYT6 neurodegeneration versus other THAP1 targets requires further dissection"]},{"year":null,"claim":"A unified model integrating how multiple transcription factors (THAP1, Nrf2, STAT3, Smad3, BRD2, Gα12/13) and post-transcriptional regulators (miR-142-3p, miR-127-3p) are hierarchically organized on the PSMB5 promoter under different physiological and stress conditions remains to be established, along with systematic identification of PSMB5-specific degradation substrates beyond Drp1 and Hobit.","evidence":"","pmids":[],"confidence":"Low","gaps":["No integrated promoter occupancy map combining all known PSMB5 transcriptional regulators exists","Systematic substrate profiling (e.g., TAILS or ubiquitin-remnant proteomics) for PSMB5-specific cleavage has not been performed","Whether PSMB5 mutations in drug-resistant tumors occur at clinically meaningful frequencies remains unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,1]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,1,11,15,18]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,21,22]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,5,6,7,9,20]}],"complexes":["20S proteasome","26S proteasome"],"partners":["LMP7","ISG20L2","THAP1","STAT3","BRD2","DRP1"],"other_free_text":[]},"mechanistic_narrative":"PSMB5 encodes the β5 catalytic subunit of the 20S proteasome, harboring a threonine-based active site that provides the principal chymotrypsin-like peptidase activity of the ubiquitin–proteasome system [PMID:8811196, PMID:9312091]. Its expression is maintained basally by THAP1 and induced by Nrf2-ARE, STAT3, Gα12/13, TGF-β/Smad3, and BRD2, while miR-142-3p and miR-127-3p post-transcriptionally repress PSMB5 levels; IFN-γ triggers displacement of PSMB5 by the immunoproteasome paralog LMP7, remodeling cleavage specificity for MHC class I antigen presentation [PMID:39929834, PMID:24627483, PMID:16723119, PMID:9382924, PMID:32866906]. Bortezomib binds directly within the PSMB5 active-site pocket at residues Ala49/Ala50, and point mutations at these positions or PSMB5 overexpression confer proteasome-inhibitor resistance by reducing drug binding and preventing ER stress–mediated apoptosis, while ISG20L2 independently competes with PSMB5 for bortezomib [PMID:18565852, PMID:19426847, PMID:20555361, PMID:36040812]. Beyond bulk proteolysis, PSMB5-dependent degradation of specific substrates such as Drp1 suppresses mitochondrial fission, and altered PSMB5 activity modulates ROS-dependent NLRP3 inflammasome activation, Hobit-driven tissue-resident memory T cell differentiation, and Nmnat2/SIRT6/NF-κB signaling in cardiac hypertrophy [PMID:30762899, PMID:36061354, PMID:39037181, PMID:33315278]."},"prefetch_data":{"uniprot":{"accession":"P28074","full_name":"Proteasome subunit beta type-5","aliases":["Macropain epsilon chain","Multicatalytic endopeptidase complex epsilon chain","Proteasome chain 6","Proteasome epsilon chain","Proteasome subunit MB1","Proteasome subunit X","Proteasome subunit beta-5","beta-5"],"length_aa":263,"mass_kda":28.5,"function":"Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). Within the 20S core complex, PSMB5 displays a chymotrypsin-like activity","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P28074/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/PSMB5","classification":"Common Essential","n_dependent_lines":1150,"n_total_lines":1208,"dependency_fraction":0.9519867549668874},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000100804","cell_line_id":"CID000107","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"nucleoplasm","grade":3}],"interactors":[{"gene":"PSMD4","stoichiometry":10.0},{"gene":"PSMC1","stoichiometry":10.0},{"gene":"PSMC5","stoichiometry":10.0},{"gene":"PSMD6","stoichiometry":10.0},{"gene":"PSME1","stoichiometry":10.0},{"gene":"PSMD2","stoichiometry":10.0},{"gene":"PSMD13","stoichiometry":10.0},{"gene":"PSMC3","stoichiometry":10.0},{"gene":"PSMA4","stoichiometry":10.0},{"gene":"PSMD1","stoichiometry":10.0}],"url":"https://opencell.sf.czbiohub.org/target/CID000107","total_profiled":1310},"omim":[{"mim_id":"618599","title":"CADHERIN 24; CDH24","url":"https://www.omim.org/entry/618599"},{"mim_id":"618048","title":"PROTEASOME-ASSOCIATED AUTOINFLAMMATORY SYNDROME 2; PRAAS2","url":"https://www.omim.org/entry/618048"},{"mim_id":"611137","title":"PROTEASOME SUBUNIT, BETA-TYPE, 11; PSMB11","url":"https://www.omim.org/entry/611137"},{"mim_id":"602175","title":"PROTEASOME SUBUNIT, BETA-TYPE, 2; PSMB2","url":"https://www.omim.org/entry/602175"},{"mim_id":"600654","title":"PROTEASOME ACTIVATOR SUBUNIT 1; PSME1","url":"https://www.omim.org/entry/600654"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Centrosome","reliability":"Additional"},{"location":"Mid piece","reliability":"Additional"},{"location":"Principal piece","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PSMB5"},"hgnc":{"alias_symbol":["MB1"],"prev_symbol":[]},"alphafold":{"accession":"P28074","domains":[{"cath_id":"3.60.20.10","chopping":"60-258","consensus_level":"high","plddt":95.0294,"start":60,"end":258}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P28074","model_url":"https://alphafold.ebi.ac.uk/files/AF-P28074-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P28074-F1-predicted_aligned_error_v6.png","plddt_mean":82.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PSMB5","jax_strain_url":"https://www.jax.org/strain/search?query=PSMB5"},"sequence":{"accession":"P28074","fasta_url":"https://rest.uniprot.org/uniprotkb/P28074.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P28074/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P28074"}},"corpus_meta":[{"pmid":"16940357","id":"PMC_16940357","title":"Testing gene function early in the B cell lineage in mb1-cre mice.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16940357","citation_count":497,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18565852","id":"PMC_18565852","title":"Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18565852","citation_count":383,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2463161","id":"PMC_2463161","title":"B lymphocyte lineage-restricted expression of mb-1, a gene with CD3-like structural properties.","date":"1988","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/2463161","citation_count":295,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20555361","id":"PMC_20555361","title":"Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.","date":"2010","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/20555361","citation_count":150,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15361869","id":"PMC_15361869","title":"Early B cell factor cooperates with Runx1 and mediates epigenetic changes associated with mb-1 transcription.","date":"2004","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15361869","citation_count":149,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1409581","id":"PMC_1409581","title":"An inhibitory carboxyl-terminal domain in Ets-1 and Ets-2 mediates differential binding of ETS family factors to promoter sequences of the mb-1 gene.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1409581","citation_count":146,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2023945","id":"PMC_2023945","title":"IgM antigen receptor complex contains phosphoprotein products of B29 and mb-1 genes.","date":"1991","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2023945","citation_count":135,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1747162","id":"PMC_1747162","title":"The IgM-associated protein mb-1 as a marker of normal and neoplastic B cells.","date":"1991","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1747162","citation_count":130,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1915300","id":"PMC_1915300","title":"A novel lineage-specific nuclear factor regulates mb-1 gene transcription at the early stages of B cell differentiation.","date":"1991","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/1915300","citation_count":125,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12651942","id":"PMC_12651942","title":"Somatic hypermutation of the B cell receptor genes B29 (Igbeta, CD79b) and mb1 (Igalpha, CD79a).","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12651942","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22235146","id":"PMC_22235146","title":"Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.","date":"2012","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/22235146","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1922076","id":"PMC_1922076","title":"Heterogeneously initiated transcription from the pre-B- and B-cell-specific mb-1 promoter: analysis of the requirement for upstream factor-binding sites and initiation site sequences.","date":"1991","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1922076","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12446773","id":"PMC_12446773","title":"Early B-cell factor, E2A, and Pax-5 cooperate to activate the early B cell-specific mb-1 promoter.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12446773","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12612069","id":"PMC_12612069","title":"Activation of the early B-cell-specific mb-1 (Ig-alpha) gene by Pax-5 is dependent on an unmethylated Ets binding site.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12612069","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10698749","id":"PMC_10698749","title":"Gene cloning and nucleotide sequencing and properties of a cocaine esterase from Rhodococcus sp. strain MB1.","date":"2000","source":"Applied and environmental microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/10698749","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2033258","id":"PMC_2033258","title":"The membrane IgM-associated heterodimer on human B cells is a newly defined B cell antigen that contains the protein product of the mb-1 gene.","date":"1991","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2033258","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2358676","id":"PMC_2358676","title":"Structure of the murine mb-1 gene encoding a putative sIgM-associated molecule.","date":"1990","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2358676","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1373499","id":"PMC_1373499","title":"The membrane IgM-associated proteins MB-1 and Ig-beta are sufficient to promote surface expression of a partially functional B-cell antigen receptor in a nonlymphoid cell line.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1373499","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18562081","id":"PMC_18562081","title":"Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.","date":"2008","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/18562081","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1396979","id":"PMC_1396979","title":"The B29 and mb-1 polypeptides are differentially expressed during human B cell differentiation.","date":"1992","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1396979","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24627483","id":"PMC_24627483","title":"Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24627483","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19426847","id":"PMC_19426847","title":"Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.","date":"2009","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/19426847","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1545794","id":"PMC_1545794","title":"BLyF, a novel cell-type- and stage-specific regulator of the B-lymphocyte gene mb-1.","date":"1992","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1545794","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7520411","id":"PMC_7520411","title":"The expression of the B-cell marker mb-1 (CD79a) in Hodgkin's disease.","date":"1994","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/7520411","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8338949","id":"PMC_8338949","title":"mb-1: a new marker for B-lineage lymphoblastic leukemia.","date":"1993","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/8338949","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29218236","id":"PMC_29218236","title":"PSMB5 plays a dual role in cancer development and immunosuppression.","date":"2017","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29218236","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9312091","id":"PMC_9312091","title":"Catalytic properties of 26 S and 20 S proteasomes and radiolabeling of MB1, LMP7, and C7 subunits associated with trypsin-like and chymotrypsin-like activities.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9312091","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1709046","id":"PMC_1709046","title":"Signal transmission through the B cell-specific MB-1 molecule at the pre-B cell stage.","date":"1991","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1709046","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3300849","id":"PMC_3300849","title":"GABAergic input to the synaptic terminals of mb1 bipolar cells in the goldfish retina.","date":"1987","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/3300849","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10395910","id":"PMC_10395910","title":"Structure analysis of a class II transposon encoding the mercury resistance of the Gram-positive Bacterium bacillus megaterium MB1, a strain isolated from minamata bay, Japan.","date":"1999","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/10395910","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1729378","id":"PMC_1729378","title":"Human mb-1 gene: complete cDNA sequence and its expression in B cells bearing membrane Ig of various isotypes.","date":"1992","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1729378","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16723119","id":"PMC_16723119","title":"Induction of 26S proteasome subunit PSMB5 by the bifunctional inducer 3-methylcholanthrene through the Nrf2-ARE, but not the AhR/Arnt-XRE, pathway.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16723119","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26519703","id":"PMC_26519703","title":"Production, extraction and stabilization of lutein from microalga Chlorella sorokiniana MB-1.","date":"2015","source":"Bioresource technology","url":"https://pubmed.ncbi.nlm.nih.gov/26519703","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3466174","id":"PMC_3466174","title":"MB1, a quail leukocyte-endothelium antigen: partial characterization of the cell surface and secreted forms in cultured endothelial cells.","date":"1986","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3466174","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32866906","id":"PMC_32866906","title":"Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis.","date":"2020","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32866906","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1538135","id":"PMC_1538135","title":"Molecular cloning and expression pattern of a human gene homologous to the murine mb-1 gene.","date":"1992","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1538135","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10548738","id":"PMC_10548738","title":"Identification of three merB genes and characterization of a broad-spectrum mercury resistance module encoded by a class II transposon of Bacillus megaterium strain MB1.","date":"1999","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/10548738","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8473731","id":"PMC_8473731","title":"Cross-linking of B cell receptor-related MB-1 molecule induces protein tyrosine phosphorylation in early B lineage cells.","date":"1993","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8473731","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16547702","id":"PMC_16547702","title":"Expression of mercuric reductase from Bacillus megaterium MB1 in eukaryotic microalga Chlorella sp. DT: an approach for mercury phytoremediation.","date":"2006","source":"Applied microbiology and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/16547702","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1993847","id":"PMC_1993847","title":"Direct identification of the putative surface IgM receptor-associated molecule encoded by murine B cell-specific mb-1 gene.","date":"1991","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1993847","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33315278","id":"PMC_33315278","title":"EGCG inhibits pressure overload-induced cardiac hypertrophy via the PSMB5/Nmnat2/SIRT6-dependent signalling pathways.","date":"2021","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/33315278","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8454258","id":"PMC_8454258","title":"Expression of the Ig-associated heterodimer (mb-1 and B29) in Hodgkin's disease.","date":"1993","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/8454258","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30762899","id":"PMC_30762899","title":"Ilexgenin A inhibits mitochondrial fission and promote Drp1 degradation by Nrf2-induced PSMB5 in endothelial cells.","date":"2019","source":"Drug development research","url":"https://pubmed.ncbi.nlm.nih.gov/30762899","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6576979","id":"PMC_6576979","title":"Primary structure of human class II histocompatibility antigens 3rd communication. Amino acid sequence comparison between DR and DC subclass antigens derived from a lymphoblastoid B cell line homozygous at the HLA loci (HLA-A3,3; B7,7; Dw2,2; DR2,2: MT1,1; Dc1,1: MB1,1).","date":"1983","source":"Hoppe-Seyler's Zeitschrift fur physiologische Chemie","url":"https://pubmed.ncbi.nlm.nih.gov/6576979","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24184088","id":"PMC_24184088","title":"Complete genome sequence of the hydrogenotrophic Archaeon Methanobacterium sp. Mb1 isolated from a production-scale biogas plant.","date":"2013","source":"Journal of biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/24184088","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28623645","id":"PMC_28623645","title":"PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.","date":"2018","source":"The International journal of biological markers","url":"https://pubmed.ncbi.nlm.nih.gov/28623645","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8144881","id":"PMC_8144881","title":"Identification of a 52-kDa molecule (p52) coprecipitated with the Ig receptor-related MB-1 protein that is inducibly phosphorylated by the stimulation with phorbol myristate acetate.","date":"1994","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8144881","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3323430","id":"PMC_3323430","title":"Immunohistochemical staining of non-Hodgkin's lymphoma in paraffin sections using the MB1 and MT1 monoclonal antibodies.","date":"1987","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/3323430","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31562641","id":"PMC_31562641","title":"Transcriptional downregulation of miR-127-3p by CTCF promotes prostate cancer bone metastasis by targeting PSMB5.","date":"2019","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/31562641","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8743292","id":"PMC_8743292","title":"VLA-beta 1 integrin subunit-specific monoclonal antibodies MB1.1 and MB1.2: binding to epitopes not dependent on thymocyte development or regulated by phorbol ester and divalent cations.","date":"1996","source":"Hybridoma","url":"https://pubmed.ncbi.nlm.nih.gov/8743292","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9636274","id":"PMC_9636274","title":"Design, expression, and initial characterization of MB1, a de novo protein enriched in essential amino acids.","date":"1995","source":"Bio/technology (Nature Publishing Company)","url":"https://pubmed.ncbi.nlm.nih.gov/9636274","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8326121","id":"PMC_8326121","title":"Surface transport and internalization of the membrane IgM H chain in the absence of the Mb-1 and B29 proteins.","date":"1993","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8326121","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6411812","id":"PMC_6411812","title":"Dissociation in expression of MB1/MT1 and DR1 alloantigens in mutants of a lymphoblastoid cell line.","date":"1983","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/6411812","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8207205","id":"PMC_8207205","title":"Structure, chromosomal localization, and methylation pattern of the human mb-1 gene.","date":"1994","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8207205","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8747711","id":"PMC_8747711","title":"The novel variants of mb-1 and B29 transcripts generated by alternative mRNA splicing.","date":"1995","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/8747711","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24393841","id":"PMC_24393841","title":"Ameliorating replicative senescence of human bone marrow stromal cells by PSMB5 overexpression.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24393841","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7514267","id":"PMC_7514267","title":"Isolation and chemical characterization of the human B29 and mb-1 proteins of the B cell antigen receptor complex.","date":"1994","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7514267","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20478922","id":"PMC_20478922","title":"G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.","date":"2010","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/20478922","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19243813","id":"PMC_19243813","title":"Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer.","date":"2009","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19243813","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8656670","id":"PMC_8656670","title":"Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia.","date":"1996","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/8656670","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15755860","id":"PMC_15755860","title":"Estrogen receptor-alpha splice variants in the medial mamillary nucleus of Alzheimer's disease patients: identification of a novel MB1 isoform.","date":"2005","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15755860","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11907094","id":"PMC_11907094","title":"Bob1 (OCA-B/OBF-1) differential transactivation of the B cell-specific B29 (Ig beta) and mb-1 (Ig alpha) promoters.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11907094","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1395095","id":"PMC_1395095","title":"Structure and expression of the mb-1 transcript in human lymphoid cells.","date":"1992","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1395095","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6083600","id":"PMC_6083600","title":"Role of HLA class II products in proliferative T-lymphocyte responses to PPD. Evidence of a regulatory influence associated with MB1.","date":"1984","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/6083600","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32301004","id":"PMC_32301004","title":"The role of PSMB5 in sodium arsenite-induced oxidative stress in L-02 cells.","date":"2020","source":"Cell stress & chaperones","url":"https://pubmed.ncbi.nlm.nih.gov/32301004","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9352537","id":"PMC_9352537","title":"Intratumoral microdistribution of [131I]MB-1 in patients with B-cell lymphoma following radioimmunotherapy.","date":"1997","source":"Nuclear medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/9352537","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9284836","id":"PMC_9284836","title":"Effects of basic fibroblast growth factor on the differentiation, growth, and viability of a new human medulloblastoma cell line (UM-MB1).","date":"1997","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9284836","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17368651","id":"PMC_17368651","title":"Age-dependent ERalpha MB1 splice variant expression in discrete areas of the human brain.","date":"2007","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/17368651","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6334638","id":"PMC_6334638","title":"[Primary structure of human class II histocompatibility antigens (HLA-D). I. Isolation, purification and characterization of the HLA-D alpha/beta chain complex from a homozygous lymphoblastoid B cell line, H2LCL (HLA-A3,3;B7,7;Dw2, 2;DR2,2;MT1,1;DC1,1;MB1,1].","date":"1984","source":"Hoppe-Seyler's Zeitschrift fur physiologische Chemie","url":"https://pubmed.ncbi.nlm.nih.gov/6334638","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28807746","id":"PMC_28807746","title":"20-HETE regulated PSMB5 expression via TGF-β/Smad signaling pathway.","date":"2017","source":"Prostaglandins & other lipid mediators","url":"https://pubmed.ncbi.nlm.nih.gov/28807746","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35617426","id":"PMC_35617426","title":"Identification of PSMB5 as a genetic modifier of fragile X-associated tremor/ataxia syndrome.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35617426","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16467989","id":"PMC_16467989","title":"Biotransformation of citrinin to decarboxycitrinin using an organic solvent-tolerant marine bacterium, Moraxella sp. MB1.","date":"2006","source":"Marine biotechnology (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/16467989","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7927516","id":"PMC_7927516","title":"Tyrosine phosphorylation of MB-1, B29, and HS1 proteins in human B cells following receptor crosslinking.","date":"1994","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/7927516","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9382924","id":"PMC_9382924","title":"Structural analysis and chromosomal localization of the mouse Psmb5 gene coding for the constitutively expressed beta-type proteasome subunit.","date":"1997","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/9382924","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24351750","id":"PMC_24351750","title":"Leuconostoc citreum MB1 as biocontrol agent of Listeria monocytogenes in milk.","date":"2013","source":"The Journal of dairy research","url":"https://pubmed.ncbi.nlm.nih.gov/24351750","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11000405","id":"PMC_11000405","title":"An essential octamer motif in the mb-1 (Igalpha) promoter.","date":"2000","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11000405","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8753855","id":"PMC_8753855","title":"Divergent intron arrangement in the MB1/LMP7 proteasome gene pair.","date":"1996","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/8753855","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2443255","id":"PMC_2443255","title":"MB1, a quail leukocyte/vascular endothelium antigen: characterization of the lymphocyte-surface form and identification of its secreted counterpart as alpha 2-macroglobulin.","date":"1987","source":"Cell differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/2443255","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7506545","id":"PMC_7506545","title":"Induction of tyrosine phosphorylation in human B lineage cells by crosslinking MB-1 molecule of B cell receptor-related heterodimer complex.","date":"1993","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/7506545","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8144961","id":"PMC_8144961","title":"Ig heavy chain extracellular spacer confers unique glycosylation of the Mb-1 component of the B cell antigen receptor complex.","date":"1994","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8144961","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10336631","id":"PMC_10336631","title":"Characterization of MB-1. A dimeric helical protein with a compact core.","date":"1999","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10336631","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8758204","id":"PMC_8758204","title":"How to differentiate between T-cell-rich B-cell lymphoma and lymphocyte-predominant Hodgkin's disease. Evidence for the value of MB1 and 4KB5 immunostaining.","date":"1996","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8758204","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11814690","id":"PMC_11814690","title":"Sequencing of amphioxus PSMB5/8 gene and phylogenetic position of agnathan sequences.","date":"2002","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11814690","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2904980","id":"PMC_2904980","title":"Immunohistochemical characterization of osteoclasts and osteoclast-like cells with monoclonal antibody MB1 on paraffin-embedded tissues.","date":"1988","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/2904980","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9204520","id":"PMC_9204520","title":"Prediction of folding stability and degradability of the de novo designed protein MB-1 in cow rumen.","date":"1997","source":"Applied biochemistry and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/9204520","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3890983","id":"PMC_3890983","title":"Mb1, a plasma membrane antigen selectively expressed by U-937 cells.","date":"1985","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/3890983","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36040812","id":"PMC_36040812","title":"ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.","date":"2022","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36040812","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15785850","id":"PMC_15785850","title":"Natural selection during functional divergence to LMP7 and proteasome subunit X (PSMB5) following gene duplication.","date":"2005","source":"Journal of molecular evolution","url":"https://pubmed.ncbi.nlm.nih.gov/15785850","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36061354","id":"PMC_36061354","title":"PSMB5 Alleviates Ulcerative Colitis by Inhibiting ROS-Dependent NLRP3 Inflammasome-Mediated Pyroptosis.","date":"2022","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/36061354","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8032536","id":"PMC_8032536","title":"Down-regulation of membrane immunoglobulin-associated proteins, MB-1, B29 and Lyn, in AIDS-lymphomas and related conditions.","date":"1994","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8032536","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39037181","id":"PMC_39037181","title":"Mitochondrial Control of Proteasomal Psmb5 Drives the Differentiation of Tissue-Resident Memory T Cells in Patients with Rheumatoid Arthritis.","date":"2024","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/39037181","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39952963","id":"PMC_39952963","title":"The DYT6 dystonia causative protein THAP1 is responsible for proteasome activity via PSMB5 transcriptional regulation.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39952963","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33649533","id":"PMC_33649533","title":"Mitochondrial uncoupler MB1-47 is efficacious in treating hepatic metastasis of pancreatic cancer in murine tumor transplantation models.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33649533","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34394840","id":"PMC_34394840","title":"Recombinant High-Mobility Group Box 1 (rHMGB1) Promotes NRF2-Independent Mitochondrial Fusion through CXCR4/PSMB5-Mediated Drp1 Degradation in Endothelial Cells.","date":"2021","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/34394840","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10982233","id":"PMC_10982233","title":"Development of an optimized feeding technology for dairy cows: improvement in resistance to ruminal proteases in the de novo-designed protein MB-1.","date":"2000","source":"Applied biochemistry and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/10982233","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9171887","id":"PMC_9171887","title":"Regulatory elements of the mb-1 gene encoding the Ig-alpha component of the human B-cell antigen receptor.","date":"1996","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9171887","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39929834","id":"PMC_39929834","title":"Loss-of-function mutations in the dystonia gene THAP1 impair proteasome function by inhibiting PSMB5 expression.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39929834","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1636436","id":"PMC_1636436","title":"Distribution of antigens detected with MB1, MB2 and MB3 on non-hematopoietic human organs and various tumors.","date":"1992","source":"Acta pathologica japonica","url":"https://pubmed.ncbi.nlm.nih.gov/1636436","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32007504","id":"PMC_32007504","title":"Participation of a MADS-box transcription factor, Mb1, in regulation of the biocontrol potential in an insect fungal pathogen.","date":"2020","source":"Journal of invertebrate pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32007504","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38009004","id":"PMC_38009004","title":"Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation.","date":"2023","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/38009004","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8811196","id":"PMC_8811196","title":"Structure and functions of the 20S and 26S proteasomes.","date":"1996","source":"Annual review of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8811196","citation_count":2108,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12167863","id":"PMC_12167863","title":"Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12167863","citation_count":1924,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22658674","id":"PMC_22658674","title":"Insights into RNA biology from an atlas of mammalian mRNA-binding proteins.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22658674","citation_count":1718,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19489727","id":"PMC_19489727","title":"Recognition and processing of ubiquitin-protein conjugates by the proteasome.","date":"2009","source":"Annual review of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19489727","citation_count":1398,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21906983","id":"PMC_21906983","title":"Systematic and quantitative assessment of the ubiquitin-modified proteome.","date":"2011","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/21906983","citation_count":1334,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19615732","id":"PMC_19615732","title":"Defining the human deubiquitinating enzyme interaction landscape.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19615732","citation_count":1282,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12808466","id":"PMC_12808466","title":"Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.","date":"2003","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12808466","citation_count":1236,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12809610","id":"PMC_12809610","title":"DNA deamination mediates innate immunity to retroviral infection.","date":"2003","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/12809610","citation_count":1150,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14564014","id":"PMC_14564014","title":"Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.","date":"2003","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/14564014","citation_count":1006,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12808465","id":"PMC_12808465","title":"The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.","date":"2003","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12808465","citation_count":912,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23503661","id":"PMC_23503661","title":"Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization.","date":"2013","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23503661","citation_count":870,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19490893","id":"PMC_19490893","title":"A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19490893","citation_count":843,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14743216","id":"PMC_14743216","title":"A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway.","date":"2004","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/14743216","citation_count":841,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29507755","id":"PMC_29507755","title":"VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation.","date":"2018","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/29507755","citation_count":829,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14528300","id":"PMC_14528300","title":"The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.","date":"2003","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/14528300","citation_count":798,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12859895","id":"PMC_12859895","title":"Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.","date":"2003","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/12859895","citation_count":763,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21890473","id":"PMC_21890473","title":"A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles.","date":"2011","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/21890473","citation_count":749,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17353931","id":"PMC_17353931","title":"Large-scale mapping of human protein-protein interactions by mass spectrometry.","date":"2007","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/17353931","citation_count":733,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14528301","id":"PMC_14528301","title":"HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.","date":"2003","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/14528301","citation_count":679,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26472760","id":"PMC_26472760","title":"Gene essentiality and synthetic lethality in haploid human cells.","date":"2015","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/26472760","citation_count":657,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14527406","id":"PMC_14527406","title":"HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.","date":"2003","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/14527406","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50803,"output_tokens":5426,"usd":0.1169},"stage2":{"model":"claude-opus-4-6","input_tokens":8998,"output_tokens":4043,"usd":0.219098},"total_usd":0.745309,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":62304,"output_tokens":8472,"usd":0.156996},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":10997,"output_tokens":4529,"usd":0.252315}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"An Ala49Thr mutation in the bortezomib-binding pocket of PSMB5 (the proteasome β5 subunit) confers high-level bortezomib resistance, alongside dramatic overexpression of PSMB5 protein (up to 60-fold); siRNA-mediated silencing of PSMB5 restored bortezomib sensitivity, establishing PSMB5 as the direct molecular target of bortezomib.\",\n      \"method\": \"Drug-resistance selection, sequencing of PSMB5 gene, Western blot for protein overexpression, cross-resistance profiling, siRNA knockdown with cytotoxicity readout\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in a single study, replicated by multiple subsequent labs\",\n      \"pmids\": [\"18565852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"A G322A mutation in PSMB5 (Ala49Thr) in bortezomib-resistant myeloma cells causes conformational changes in the bortezomib-binding pocket, reduces accumulation of polyubiquitinated proteins, and prevents catastrophic ER stress; transfection of mutant PSMB5 into parental cells recapitulated reduced bortezomib-induced apoptosis, directly linking the PSMB5 mutation to suppression of unfolded protein accumulation.\",\n      \"method\": \"Sequencing, transfection of mutant vs. wild-type PSMB5, Western blot for polyubiquitinated proteins and CHOP, caspase activation assays\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional rescue experiment with mutant vs. wild-type PSMB5, multiple readouts\",\n      \"pmids\": [\"20555361\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Different point mutations at Ala49 (G322A → Ala49Thr; C323T → Ala49Val) and a double mutant (G322A/C326T → Ala49Thr/Ala50Val) of PSMB5 confer progressively increasing levels of bortezomib resistance (22-, 39-, and 67-fold respectively), correlating with progressively reduced inhibition of chymotrypsin-like proteasome activity.\",\n      \"method\": \"Selection of resistant clones, cDNA sequencing, chymotrypsin-like proteasome activity assay (fluorogenic substrate), cytotoxicity assay\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — multiple distinct mutants correlated with functional proteasome activity measurements\",\n      \"pmids\": [\"19426847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"PSMB5 (MB1 subunit) harbors catalytic activity associated with chymotrypsin-like peptidase activity of the 20S proteasome; radiolabeled active-site-directed inhibitors (chloromethane and diazomethane peptides) were incorporated into MB1, LMP7, and C7 subunits, and blockade with known active-site inhibitors prevented labeling, demonstrating that PSMB5 contains a catalytic active site responsible for chymotrypsin-like cleavage.\",\n      \"method\": \"Radiolabeled active-site-directed inhibitor labeling, 2D-PAGE, immunoblotting with subunit-specific antibodies, kinetic assays of 20S and 26S proteasomes\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — active-site directed covalent labeling with mutagenesis-equivalent controls, demonstrating catalytic identity\",\n      \"pmids\": [\"9312091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The mouse Psmb5 gene (constitutively expressed β5 proteasome subunit) is displaced from the 20S proteasome by LMP7 (PSMB8) upon IFN-γ stimulation, with this subunit exchange altering proteasome cleavage specificities to facilitate MHC class I antigen presentation.\",\n      \"method\": \"Gene structure analysis, interspecific backcross mapping, FISH chromosomal localization, comparative analysis of IFN-γ regulation\",\n      \"journal\": \"Immunogenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — structural gene analysis supporting functional inference established by prior biochemical literature\",\n      \"pmids\": [\"9382924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PSMB5 mutations (in the bortezomib-binding pocket) confer cross-resistance to second-generation proteasome inhibitors (carfilzomib, ONX0912, ONX0914) but with varying degrees, establishing that the β5 subunit binding pocket is the shared pharmacological target; P-glycoprotein-mediated efflux constitutes a separate, PSMB5-independent resistance mechanism.\",\n      \"method\": \"Drug resistance profiling in THP1 sublines with PSMB5 mutations vs. CEM/VLB cells with Pgp overexpression, chymotrypsin-like proteasome activity assays\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — orthogonal resistance mechanisms dissected in isogenic cell line pairs with activity measurements\",\n      \"pmids\": [\"22235146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Overexpression of PSMB5 (via gene amplification, i(14q)) is an independent mechanism of bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells; increased PSMB5 mRNA correlated with increased chymotrypsin-like proteasome activity and reduced IκB-α degradation by bortezomib, indicating NF-κB dysregulation as a downstream consequence.\",\n      \"method\": \"Quantitative RT-PCR, FISH for gene amplification, fluorogenic chymotrypsin-like proteasome activity assay, Western blot for IκB-α\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gene copy number correlated with mRNA/activity, but no direct functional rescue experiment\",\n      \"pmids\": [\"18562081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PSMB5 expression is transcriptionally induced by the Nrf2-ARE pathway (not AhR/Arnt-XRE): mutation of proximal AREs in the Psmb5 promoter largely abolished inducibility by 3-methylcholanthrene, and Nrf2 knockout blunted the response, identifying Nrf2 as a transcriptional regulator of PSMB5.\",\n      \"method\": \"Reporter gene assays with ARE/XRE mutant Psmb5 promoter constructs, overexpression of AhR/Arnt, Nrf2 knockout cells, nuclear Nrf2 localization\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — promoter mutagenesis + genetic knockout with functional reporter readout\",\n      \"pmids\": [\"16723119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"STAT3 transcriptionally regulates PSMB5 expression: constitutively active STAT3 induces PSMB5 promoter activity and protein levels, STAT3 knockdown coordinately reduces PSMB5 and β subunit levels, and combined bortezomib + STAT3 inhibition synergistically abrogates proteasome activity and enhances apoptosis.\",\n      \"method\": \"STAT3 knockdown/overexpression, PSMB5 promoter-luciferase assay, Western blot, proteasome activity assay, apoptosis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — promoter assay + gain- and loss-of-function experiments with multiple readouts\",\n      \"pmids\": [\"24627483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ISG20L2 competes with PSMB5 for bortezomib binding, attenuating drug inhibition of proteasome activity; biotinylated bortezomib pull-down and surface plasmon resonance confirmed direct ISG20L2–bortezomib interaction, establishing a non-mutational resistance mechanism via steric competition at the PSMB5 drug-binding site.\",\n      \"method\": \"Biotinylated bortezomib pull-down assay, surface plasmon resonance (direct binding), gain- and loss-of-function studies, proteasome activity assay\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding confirmed by two orthogonal methods (pull-down + SPR) plus functional proteasome activity readout\",\n      \"pmids\": [\"36040812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The transcription factor THAP1 directly regulates PSMB5 gene expression; THAP1 depletion reduces PSMB5 transcription, disrupts proteasome assembly, impairs proteostasis (accumulation of ubiquitinated proteins), and causes cell death; exogenous PSMB5 expression rescues toxicity from THAP1 loss, placing THAP1 upstream of PSMB5 in proteasome biogenesis.\",\n      \"method\": \"Genome-wide genetic screen (DepMap coessentiality), RNA-seq, THAP1 knockdown/knockout with PSMB5 rescue, ubiquitinated protein accumulation assay, deep mutational scan of THAP1 variants\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — genome-wide screen + genetic rescue + multiple functional readouts, two independent labs (PMIDs 39929834 and 39952963)\",\n      \"pmids\": [\"39929834\", \"39952963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PSMB5 overexpression in late-stage senescent human bone marrow stromal cells restores 20S proteasome activity, promotes cell proliferation (via Cyclin D1/CDK4 upregulation), enhances resistance to oxidative stress, and retains pluripotency; conversely, PSMB5 knockdown in early-stage cells reduces proteasome activity and induces a senescent phenotype.\",\n      \"method\": \"PSMB5 overexpression and siRNA knockdown, proteasome activity assay, cell proliferation assay, Western blot for Cyclin D1/CDK4, H2O2 oxidative stress challenge, in vitro/in vivo neural differentiation\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain- and loss-of-function with multiple mechanistic readouts\",\n      \"pmids\": [\"24393841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Curcumin reduces PSMB5 protein levels via a p300/miR-142-3p axis: curcumin suppresses p300 histone acetyltransferase activity, elevating miR-142-3p which directly targets and represses PSMB5 translation, leading to reduced chymotrypsin-like (CT-l) activity of the 20S proteasome.\",\n      \"method\": \"miRNA overexpression/inhibition, PSMB5 knockdown, reporter assay confirming miR-142-3p targeting of PSMB5 3'UTR, Western blot, proteasome activity assay, in vivo xenograft\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct miRNA-target validation plus upstream p300 mechanism, single lab\",\n      \"pmids\": [\"32866906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TGF-β/Smad3 signaling directly regulates PSMB5 transcription: Smad3 binds to the Smad binding element (SBE) of the Psmb5 promoter (confirmed by EMSA and luciferase assay), and 20-HETE modulates this pathway in a tissue-specific manner (upregulating in liver, downregulating in kidney); TGF-β receptor I kinase inhibitor SB431542 reversed 20-HETE effects on PSMB5 in vitro.\",\n      \"method\": \"Luciferase reporter assay with Psmb5 promoter, EMSA with Smad3, transgenic mice (CYP4F2), TGF-β receptor inhibitor\",\n      \"journal\": \"Prostaglandins & other lipid mediators\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1/2 — direct DNA-binding (EMSA) + promoter reporter + genetic/pharmacological intervention, single lab\",\n      \"pmids\": [\"28807746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PSMB5 promotes Drp1 degradation via proteasomal activity: Nrf2-induced PSMB5 upregulation suppresses mitochondrial fission by degrading Drp1, and proteasome inhibitor epoxomicin abrogated this effect; Nrf2 knockdown eliminated IA-induced PSMB5 expression and mitochondrial fission inhibition.\",\n      \"method\": \"PSMB5 overexpression, Nrf2 knockdown (siRNA), epoxomicin proteasome inhibitor, Western blot for Drp1 and PSMB5, mitochondrial morphology imaging\",\n      \"journal\": \"Drug development research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and genetic dissection with functional mitochondrial readout, single lab\",\n      \"pmids\": [\"30762899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PSMB5 (chymotrypsin-like proteasome activity) is required for EGCG-induced Nmnat2 protein expression and subsequent SIRT6 activation; EGCG may interact directly with PSMB5 (suggested by molecular interaction data) and inhibit proteasome activation, with PSMB5 activation being upstream of Nmnat2 in an anti-cardiac hypertrophy pathway.\",\n      \"method\": \"RNA interference (Nmnat2 knockdown), PSMB5 activity assay, NF-κB EMSA, luciferase reporter, SIRT6 activity assay, in vivo pressure overload model\",\n      \"journal\": \"Acta physiologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis established by knockdown and pharmacological inhibition with multiple functional readouts, single lab\",\n      \"pmids\": [\"33315278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PSMB5 (Prosbeta5 in Drosophila) genetically modifies CGG-repeat neurotoxicity in FXTAS: knockdown of PSMB5 suppressed CGG-associated neurodegeneration in Drosophila and N2A cells, acting through both RAN translation and RNA-mediated toxicity mechanisms; an eQTL variant (PSMB5rs11543947-A) associated with decreased PSMB5 expression correlated with delayed FXTAS onset in human carriers.\",\n      \"method\": \"Drosophila genetic screen, PSMB5 knockdown (fly and mammalian cells), whole-genome sequencing of human premutation carriers, eQTL analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in Drosophila validated in mammalian cells, with human genetic correlation\",\n      \"pmids\": [\"35617426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Mitochondrial succinyl-CoA drives succinylation of BRD2, which inhibits BRD2-mediated transcription of PSMB5; reduced PSMB5 expression in RA T cells elevates Hobit protein (by impairing proteasomal degradation), promoting CD4+ Trm cell differentiation; this pathway was validated by chromatin immunoprecipitation showing BRD2 binding to the PSMB5 promoter and by succinyl-CoA manipulation reversing the phenotype.\",\n      \"method\": \"Chromatin immunoprecipitation-qPCR (BRD2 at PSMB5 promoter), PSMB5 knockdown, succinyl-CoA manipulation in T cells, humanized NSG chimera model, Hobit silencing\",\n      \"journal\": \"Arthritis & rheumatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP validation + genetic/metabolic manipulation with in vivo readout, single lab\",\n      \"pmids\": [\"39037181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PSMB5 knockdown in MDA-MB-231 cells inhibits cancer cell growth and migration, and promotes THP-1 monocyte differentiation toward M1 macrophage; lentiviral delivery of PSMB5 shRNA significantly decreased tumor growth in a subcutaneous mouse model.\",\n      \"method\": \"shRNA knockdown, colony formation assay, Boyden chamber migration assay, flow cytometry for macrophage polarization, in vivo subcutaneous tumor model\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with multiple defined cellular phenotypes plus in vivo validation, single lab\",\n      \"pmids\": [\"29218236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"rHMGB1 promotes mitochondrial fusion in endothelial cells via a CXCR4/PSMB5 pathway that mediates Drp1 proteolysis: CXCR4 inhibition (AMD3100) reversed Drp1 downregulation, while PSMB5 inhibition (epoxomicin) abolished rHMGB1-induced mitochondrial fusion independently of NRF2, placing PSMB5 proteasomal activity downstream of CXCR4 signaling in regulating mitochondrial dynamics.\",\n      \"method\": \"Specific receptor inhibitors (AMD3100, TAK-242, FPS-ZM1), PSMB5 inhibitor epoxomicin, NRF2 siRNA, Western blot for Drp1, confocal/TEM for mitochondrial morphology\",\n      \"journal\": \"Oxidative medicine and cellular longevity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological epistasis with multiple pathway components and functional mitochondrial imaging, single lab\",\n      \"pmids\": [\"34394840\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PSMB5 encodes the β5 catalytic subunit of the 20S proteasome with chymotrypsin-like peptidase activity at an active-site pocket that is the direct binding site for bortezomib; mutations at Ala49/Ala50 within this pocket confer bortezomib resistance by preventing drug binding and reducing inhibition of proteasome activity; PSMB5 expression is transcriptionally regulated by Nrf2-ARE, STAT3, THAP1, TGF-β/Smad3, and BRD2 (via succinylation), while post-transcriptionally it is targeted by miR-142-3p; beyond its core proteolytic function, PSMB5-mediated proteasomal activity controls Drp1 degradation and mitochondrial dynamics, Hobit protein stability and T cell differentiation, replicative senescence via Cyclin D1/CDK4, and modulates NF-κB and ER stress responses.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper, then extract discoveries only from KEEP papers.\n\n**Classification:**\n\nPapers about PSMB5 (canonical proteasome β5 subunit): KEEP\n- [2] PMID:18565852 - PSMB5 mutation in bortezomib resistance ✓\n- [4] PMID:20555361 - PSMB5 mutation in myeloma resistance ✓\n- [11] PMID:22235146 - PSMB5 mutations and PI resistance ✓\n- [19] PMID:18562081 - PSMB5 overexpression in bortezomib resistance ✓\n- [21] PMID:24627483 - STAT3 regulates PSMB5 ✓\n- [22] PMID:19426847 - PSMB5 mutations and bortezomib resistance ✓\n- [26] PMID:29218236 - PSMB5 role in cancer/immunosuppression ✓\n- [27] PMID:9312091 - MB1 subunit catalytic properties (rat PSMB5 ortholog) ✓\n- [32] PMID:16723119 - Nrf2-ARE regulates PSMB5 ✓\n- [35] PMID:32866906 - Curcumin/p300/miR-142-3p/PSMB5 ✓\n- [41] PMID:33315278 - EGCG/PSMB5/Nmnat2/SIRT6 cardiac hypertrophy ✓\n- [43] PMID:30762899 - Nrf2/PSMB5/Drp1 degradation ✓\n- [49] PMID:31562641 - CTCF/miR-127-3p/PSMB5 axis ✓\n- [56] PMID:24393841 - PSMB5 overexpression ameliorates senescence ✓\n- [58] PMID:20478922 - Gα12/13 inhibition affects PSMB5 ✓\n- [65] PMID:32301004 - PSMB5 in arsenite-induced oxidative stress ✓\n- [70] PMID:28807746 - 20-HETE/TGF-β/Smad regulates PSMB5 ✓\n- [71] PMID:35617426 - PSMB5 as genetic modifier of FXTAS ✓\n- [74] PMID:9382924 - Mouse Psmb5 gene structure ✓\n- [77] PMID:8753855 - MB1/LMP7 gene structure (PSMB5 gene) ✓\n- [83] PMID:11814690 - Amphioxus PSMB5/8 phylogeny ✓\n- [87] PMID:36040812 - ISG20L2 competes with PSMB5 for bortezomib ✓\n- [88] PMID:15785850 - PSMB5/LMP7 gene duplication ✓\n- [89] PMID:36061354 - PSMB5 and NLRP3 inflammasome ✓\n- [91] PMID:39037181 - Mitochondrial control of Psmb5 in RA T cells ✓\n- [92] PMID:39952963 - THAP1 regulates PSMB5 transcription ✓\n- [94] PMID:34394840 - CXCR4/PSMB5-mediated Drp1 degradation ✓\n- [97] PMID:39929834 - THAP1 regulates PSMB5 ✓\n- [100] PMID:38009004 - STAT3/PSMB5 in bortezomib resistance ✓\n\nAdditional curated:\n- [1] PMID:8811196 - Structure/function of proteasome (foundational, PSMB5 context) ✓\n- [5] PMID:19489727 - Proteasome function review ✓\n\nEXCLUDE (mb-1/CD79a papers, unrelated MB1 symbols, APOBEC3G papers, interactome papers unrelated to PSMB5, etc.):\nPapers [1],[3],[5],[6],[7],[8],[9],[10],[12],[13],[14],[15],[16],[17],[18],[20],[23],[24],[25],[28],[29],[30],[31],[33],[34],[36],[37],[38],[39],[40],[42],[44],[45],[46],[47],[48],[50],[51],[52],[53],[54],[55],[57],[59],[60],[61],[62],[63],[64],[66],[67],[68],[69],[72],[73],[75],[76],[78],[79],[80],[81],[82],[84],[85],[86],[90],[93],[95],[96],[98],[99] from main corpus.\n\nAdditional curated [2],[3],[4],[6],[7],[8],[9],[10],[11],[12],[13],[14],[15],[16],[17],[18],[19],[20],[21],[22],[23],[24],[25],[26],[27],[28],[29],[30] — these are APOBEC3G, interactome, ubiquitin proteomics papers unrelated to PSMB5 mechanism → EXCLUDE.\n\nAdditional curated [1] PMID:8811196 — foundational proteasome review, KEEP for context.\nAdditional curated [5] PMID:19489727 — proteasome function review, KEEP.\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"Radiolabeling of 20S and 26S proteasomes with active-site-directed peptidyl chloromethane and diazomethane inhibitors showed that the MB1 subunit (PSMB5) is one of the catalytic components associated with chymotrypsin-like and trypsin-like peptidase activities; incorporation of label into PSMB5 was blocked by prior treatment with calpain inhibitor or 3,4-dichloroisocoumarin, confirming active-site involvement.\",\n      \"method\": \"Radiolabeled active-site inhibitor labeling, 2D-PAGE, HPLC, immunoblotting with subunit-specific antibodies\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro active-site labeling with multiple inhibitors and orthogonal separation methods\",\n      \"pmids\": [\"9312091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The 20S proteasome β5 subunit (PSMB5/MB1) harbors a threonine-based active site and contributes to the chymotrypsin-like peptidase activity of the multicatalytic protease complex; the 26S proteasome (formed by association of 20S with the 19S regulatory complex) degrades ubiquitinated proteins in an ATP-dependent manner.\",\n      \"method\": \"Biochemical purification, kinetic analysis, active-site characterization (review synthesizing multiple labs' reconstitution and inhibitor studies)\",\n      \"journal\": \"Annual Review of Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple independent labs, reconstitution and active-site mutagenesis, widely replicated\",\n      \"pmids\": [\"8811196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The mouse Psmb5 gene encoding the constitutively expressed β5 proteasome subunit is composed of three exons spanning ~5 kb, with a unique exon-intron organization radically different from its paralog Lmp7 (PSMB8), suggesting distinct evolutionary history; upon IFN-γ stimulation, PSMB5 is displaced from the 20S proteasome by LMP7, altering cleavage specificity to facilitate MHC class I antigen presentation.\",\n      \"method\": \"Genomic cloning, sequencing, interspecific backcross mapping, fluorescence in situ hybridization\",\n      \"journal\": \"Immunogenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and structural characterization, functional inference from IFN-γ displacement well established by prior work\",\n      \"pmids\": [\"9382924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PSMB5 expression is transcriptionally induced by the bifunctional enzyme inducer 3-methylcholanthrene through the Nrf2-ARE pathway but not through the AhR/Arnt-XRE pathway; mutation of the proximal AREs in the Psmb5 promoter abolished inducibility, and 3-MC failed to induce PSMB5 in nrf2-null cells.\",\n      \"method\": \"Luciferase reporter assay with ARE/XRE deletion/mutation constructs, overexpression of AhR/Arnt, nrf2-null cell comparison, nuclear Nrf2 level measurement\",\n      \"journal\": \"Biochemical and Biophysical Research Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — promoter mutagenesis plus genetic null cell validation, multiple orthogonal approaches in one study\",\n      \"pmids\": [\"16723119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Acquired bortezomib resistance in THP1 myelomonocytic cells is associated with (1) an Ala49Thr point mutation in the bortezomib-binding pocket of PSMB5 and (2) selective overexpression of PSMB5 protein up to 60-fold without comparable upregulation of other proteasome subunits; siRNA-mediated silencing of PSMB5 restored bortezomib sensitivity, confirming PSMB5 as the direct resistance determinant.\",\n      \"method\": \"DNA sequencing, Western blot, siRNA knockdown, cytotoxicity assays, chymotrypsin-like activity assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mutation identification + siRNA rescue + activity assay, multiple orthogonal methods, widely replicated\",\n      \"pmids\": [\"18565852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Overexpression and gene amplification of PSMB5 (demonstrated by FISH) in bortezomib-resistant Jurkat T-lymphoblastic leukemia cells increases chymotrypsin-like proteasome activity and correlates with upregulated NF-κB activity after bortezomib treatment, suggesting PSMB5 amplification-driven resistance operates through sustained NF-κB pathway.\",\n      \"method\": \"RT-qPCR, in situ hybridization/FISH, fluorometric chymotrypsin-like activity assay, Western blot for IκB-α and P-gp\",\n      \"journal\": \"Experimental Hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gene amplification confirmed by FISH + functional activity assay, single lab\",\n      \"pmids\": [\"18562081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Three distinct PSMB5 mutations (G322A→Ala49Thr, C323T→Ala49Val, and compound G322A+C326T→Ala49Thr+Ala50Val) confer graded levels of bortezomib resistance (22-, 39-, and 67-fold, respectively) in Jurkat cells; resistance correlates with reduced inhibition of chymotrypsin-like activity by bortezomib, establishing that amino acids 49 and 50 of PSMB5 are critical for bortezomib binding.\",\n      \"method\": \"cDNA sequencing, limited dilution cloning, cytotoxicity assays, fluorometric chymotrypsin-like activity assay\",\n      \"journal\": \"Experimental Hematology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple independent point mutations with quantitative resistance/activity data, mechanistically informative structure-function relationship\",\n      \"pmids\": [\"19426847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"A G322A point mutation in PSMB5 in bortezomib-resistant myeloma cell lines causes conformational changes in the bortezomib-binding pocket, reducing accumulation of polyubiquitinated proteins and preventing catastrophic ER stress/CHOP induction; transfection of mutant PSMB5 into parental cells recapitulated reduced bortezomib-induced apoptosis, directly linking the PSMB5 mutation to ER stress avoidance.\",\n      \"method\": \"DNA sequencing, transfection of wild-type vs. mutant PSMB5, Western blot for polyubiquitinated proteins and CHOP, caspase/BH3-only protein analysis\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct rescue/overexpression experiment linking specific mutation to mechanistic phenotype, multiple readouts\",\n      \"pmids\": [\"20555361\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Inhibition of Gα12/13 signaling downregulates PSMB5 expression at the mRNA and protein levels, enhances bortezomib-mediated cytotoxicity, and reduces chymotrypsin-like proteasome activity; active Gα12QL or Gα13QL reversed these effects, placing Gα12/13 upstream of PSMB5 regulation.\",\n      \"method\": \"RT-PCR, Western blot, proteasome activity assay, transfection with active mutants and minigene constructs, cytotoxicity assay\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional genetic manipulation (gain and loss of function) with functional readouts, single lab\",\n      \"pmids\": [\"20478922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PSMB5 mutations (identified in bortezomib-resistant THP1 sublines) confer marked cross-resistance to second-generation proteasome inhibitors carfilzomib, ONX0912, and ONX0914, though less pronounced than to bortezomib; P-glycoprotein overexpression provides an independent resistance mechanism by reducing effective intracellular drug concentration, and Pgp inhibition with reversin 121 restores parental sensitivity.\",\n      \"method\": \"Cytotoxicity assays, β5 subunit chymotrypsin-like activity assay, flow cytometry for Pgp, Pgp inhibitor reversal experiments\",\n      \"journal\": \"The Journal of Pharmacology and Experimental Therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional activity assays across multiple inhibitors + pharmacological reversal, single lab\",\n      \"pmids\": [\"22235146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"STAT3 transcriptionally activates PSMB5 expression; knockdown of STAT3 decreases PSMB5 mRNA and protein, inhibition of phospho-STAT3 reduces PSMB5 in constitutively active-STAT3 cells, and accumulation of active STAT3 induces PSMB5 promoter activity. EGF-induced upregulation of β subunits including PSMB5 was blocked by EGFR or STAT3 inhibition but not by PI3K/AKT or MEK/ERK inhibition.\",\n      \"method\": \"STAT3 knockdown, constitutively active STAT3 overexpression, luciferase promoter assay, Western blot, RT-PCR, pathway inhibitor panel\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional STAT3 manipulation + promoter assay + pathway specificity analysis, multiple orthogonal methods\",\n      \"pmids\": [\"24627483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Overexpression of PSMB5 in late-stage senescent human bone marrow stromal cells restores 20S proteasome activity and promotes cell growth potentially via upregulating the Cyclin D1/CDK4 complex; conversely, PSMB5 knockdown in early-stage cells reduces proteasome activity and proliferation, mimicking a senescent phenotype. PSMB5 overexpression also enhances cell survival under oxidative stress and preserves pluripotency.\",\n      \"method\": \"PSMB5 overexpression and siRNA knockdown, proteasome activity assay, BrdU/proliferation assay, Western blot for Cyclin D1/CDK4, H2O2 survival assay, neural differentiation assay\",\n      \"journal\": \"Biochemical and Biophysical Research Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional manipulation with multiple functional readouts, mechanistic link to Cyclin D1/CDK4\",\n      \"pmids\": [\"24393841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"High expression of PSMB5 promotes M2 macrophage polarization and suppresses M1 differentiation; PSMB5 knockdown in THP-1 monocytes shifts differentiation toward M1 macrophages. PSMB5 knockdown in MDA-MB-231 breast cancer cells inhibits cell growth and migration. In vivo lentiviral PSMB5 shRNA delivery significantly reduced tumor growth in a subcutaneous mouse model.\",\n      \"method\": \"shRNA knockdown, colony formation assay, Boyden chamber migration assay, monocyte differentiation assay, in vivo subcutaneous tumor model\",\n      \"journal\": \"American Journal of Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined cellular phenotypes in vitro and in vivo, single lab\",\n      \"pmids\": [\"29218236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"20-HETE regulates PSMB5 expression in a tissue-specific manner through the TGF-β/Smad3 signaling pathway; Smad3 directly binds the Smad binding element (SBE) in the Psmb5 promoter as demonstrated by EMSA, and the TGF-β receptor I kinase inhibitor SB431542 reverses 20-HETE-induced changes in PSMB5 levels.\",\n      \"method\": \"Luciferase reporter assay, EMSA, TGF-β pathway inhibitor (SB431542), Western blot for TGF-β1, Smad3 phosphorylation, and PSMB5\",\n      \"journal\": \"Prostaglandins & Other Lipid Mediators\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — EMSA demonstrates direct Smad3-SBE interaction + promoter reporter + pharmacological validation, single lab\",\n      \"pmids\": [\"28807746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PSMB5 is a direct target of miR-127-3p; overexpression of miR-127-3p reduces PSMB5 protein and inhibits prostate cancer cell invasion and migration. CTCF transcription factor suppresses miR-127-3p expression by binding the miR-127-3p promoter, thereby indirectly upregulating PSMB5 to promote bone metastasis.\",\n      \"method\": \"Luciferase 3'UTR reporter assay, miR-127-3p overexpression, CTCF ChIP or promoter binding assay, invasion/migration assay\",\n      \"journal\": \"FEBS Letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct miRNA target validation with reporter assay + upstream CTCF mechanism, single lab\",\n      \"pmids\": [\"31562641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Ilexgenin A (IA) increases PSMB5 expression in an Nrf2-dependent manner in endothelial cells; Nrf2 knockdown abolishes IA-induced PSMB5 upregulation. Increased PSMB5 activity promotes proteasomal degradation of Drp1, thereby suppressing mitochondrial fission and improving endothelial function. Proteasome inhibitor epoxomicin blocked IA's effect on Drp1 expression, confirming the PSMB5-mediated degradation mechanism.\",\n      \"method\": \"Nrf2 siRNA knockdown, Western blot for PSMB5 and Drp1, proteasome inhibitor (epoxomicin) treatment, mitochondrial morphology assessment\",\n      \"journal\": \"Drug Development Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic (siRNA) and pharmacological (epoxomicin) validation of Nrf2→PSMB5→Drp1 axis, single lab\",\n      \"pmids\": [\"30762899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Curcumin elevates miR-142-3p expression by inhibiting histone acetyltransferase p300, and miR-142-3p directly targets the PSMB5 3'UTR to reduce PSMB5 protein levels and chymotrypsin-like activity of the 20S proteasome; loss of p300 and PSMB5 each independently reduced cell proliferation in triple-negative breast cancer cells.\",\n      \"method\": \"miR-142-3p mimic/inhibitor, PSMB5 3'UTR luciferase reporter, p300 overexpression, fluorometric proteasome activity assay, BrdU proliferation assay, in vivo xenograft\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct 3'UTR targeting validated by reporter + upstream p300 mechanism + in vivo confirmation, multiple orthogonal methods\",\n      \"pmids\": [\"32866906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EGCG activates PSMB5 (20S proteasome β5, chymotrypsin-like activity) and may directly interact with PSMB5; activated PSMB5 is required for EGCG-induced upregulation of Nmnat2 protein expression. Nmnat2 subsequently activates SIRT6 histone deacetylase, which blocks NF-κB DNA binding activity induced by angiotensin II, thereby inhibiting cardiac hypertrophy. PSMB5 knockdown attenuated EGCG's anti-hypertrophic effects.\",\n      \"method\": \"RNA interference (PSMB5 knockdown), luciferase reporter for NF-κB, EMSA for NF-κB DNA binding, fluorometric SIRT6 activity assay, Western blot, in vivo aortic constriction model\",\n      \"journal\": \"Acta Physiologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockdown confirms PSMB5 requirement in pathway, multiple downstream readouts, single lab\",\n      \"pmids\": [\"33315278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"rHMGB1 promotes mitochondrial fusion in endothelial cells via the CXCR4/PSMB5 pathway: rHMGB1 increases PSMB5 expression through CXCR4 (not TLR4, RAGE, or TLR2), and PSMB5 mediates proteasomal degradation of Drp1, reducing mitochondrial fission. Inhibition of PSMB5 with epoxomicin abolished rHMGB1-induced Drp1 downregulation and mitochondrial fusion, independent of NRF2.\",\n      \"method\": \"Specific receptor inhibitors (AMD3100/CXCR4, C29/TLR2, TAK-242/TLR4, FPS-ZM1/RAGE), epoxomicin (PSMB5 inhibitor), NRF2 siRNA, confocal/TEM mitochondrial morphology, Western blot\",\n      \"journal\": \"Oxidative Medicine and Cellular Longevity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and genetic dissection of receptor-PSMB5-Drp1 axis, single lab\",\n      \"pmids\": [\"34394840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PSMB5 knockdown suppresses CGG repeat-associated neurodegeneration in both Drosophila FXTAS models and N2A cells; the PSMB5 expression QTL variant rs11543947-A is associated with decreased PSMB5 expression and delayed FXTAS onset in human FMR1 premutation carriers. PSMB5 knockdown reduces toxicity via both RAN translation and RNA-mediated mechanisms.\",\n      \"method\": \"Drosophila genetic screen (whole-genome sequencing + candidate knockdown), N2A cell knockdown, human genetic association (QTL analysis), RAN translation and RNA toxicity assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cross-species epistasis (fly + mammalian cell) with human genetic validation, multiple mechanism dissection\",\n      \"pmids\": [\"35617426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ISG20L2 competes directly with PSMB5 for bortezomib binding: biotinylated bortezomib pull-down showed ISG20L2 competes with PSMB5 for drug binding, and surface plasmon resonance confirmed direct bortezomib-ISG20L2 interaction. In ISG20L2-high myeloma cells, ISG20L2 attenuates bortezomib binding to PSMB5, reducing proteasome inhibition and cell death.\",\n      \"method\": \"Biotinylated bortezomib pull-down assay, surface plasmon resonance, gain/loss-of-function in vitro and in vivo experiments, proteasome activity assay\",\n      \"journal\": \"JCI Insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding competition demonstrated by two orthogonal biochemical methods (pull-down + SPR)\",\n      \"pmids\": [\"36040812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PSMB5 overexpression in intestinal epithelial cells reduces LPS-induced NLRP3 inflammasome activation and pyroptosis by decreasing intracellular ROS generation; ROS scavenger NAC mimicked this protective effect, placing PSMB5 upstream of ROS-dependent NLRP3 activation in a model of ulcerative colitis.\",\n      \"method\": \"PSMB5 overexpression, NLRP3/caspase-1/ASC Western blot, LDH release assay, ROS measurement, NAC/Z-VAD-FMK/MCC950 pharmacological dissection, in vivo DSS colitis model\",\n      \"journal\": \"Disease Markers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — overexpression + multiple pathway inhibitors establish mechanistic order, single lab\",\n      \"pmids\": [\"36061354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In rheumatoid arthritis T cells, elevated mitochondrial succinyl-CoA causes succinylation of BRD2 transcription factor, which impairs BRD2-dependent transcription of PSMB5; reduced PSMB5 leads to accumulation of the transcription factor Hobit, promoting CD4+ T cell differentiation into tissue-resident memory (Trm) cells and synovial inflammation. ChIP-qPCR validated direct BRD2 binding to the PSMB5 promoter.\",\n      \"method\": \"BRD2 chromatin immunoprecipitation-qPCR, Hobit knockdown, succinyl-CoA manipulation, humanized NSG chimera model, Trm differentiation assay\",\n      \"journal\": \"Arthritis & Rheumatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-qPCR validates direct BRD2-PSMB5 promoter interaction + in vivo model, single lab\",\n      \"pmids\": [\"39037181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The transcription factor THAP1 (DYT6 dystonia gene) directly regulates PSMB5 gene expression to maintain basal proteasome activity; loss of THAP1 reduces PSMB5 levels, disrupts proteasome assembly, impairs proteostasis, and causes cell death. Exogenous PSMB5 expression rescues THAP1-deficient cell toxicity. A deep mutational scan of THAP1 variants correlated with PSMB5 regulatory capacity.\",\n      \"method\": \"Genome-wide CRISPR genetic screen (DepMap coessentiality), THAP1 knockout, PSMB5 exogenous rescue, proteasome assembly assay, ubiquitinated protein accumulation, RNA-seq, deep mutational scan\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genome-wide screen + genetic rescue + proteasome assembly readout + deep mutational scan, multiple orthogonal methods\",\n      \"pmids\": [\"39929834\", \"39952963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Complementary study confirms THAP1 transcriptionally activates PSMB5; THAP1 depletion decreases PSMB5 mRNA and protein, disrupts proteasome assembly, and increases ubiquitinated protein accumulation. These findings identify THAP1 as a critical regulator of proteasome function and suggest proteasome dysfunction contributes to DYT6 dystonia pathogenesis.\",\n      \"method\": \"THAP1 knockout/knockdown, Western blot, proteasome activity assay, ubiquitinated protein accumulation, RNA-seq transcriptional target definition\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — independently replicated across two contemporaneous papers using complementary approaches\",\n      \"pmids\": [\"39952963\", \"39929834\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PSMB5 encodes the β5 catalytic subunit of the 20S proteasome with a threonine-based active site responsible for chymotrypsin-like peptidase activity; its expression is transcriptionally controlled by THAP1 (basal), Nrf2-ARE (stress-induced), STAT3, Gα12/13, TGF-β/Smad3, BRD2, and miRNAs including miR-142-3p and miR-127-3p; it is displaced by the IFN-γ-inducible paralog LMP7 to remodel proteasome specificity for antigen presentation; bortezomib binds directly in the PSMB5 active-site pocket (residues Ala49/Ala50 are critical), and point mutations at these residues or PSMB5 overexpression confer bortezomib resistance by reducing drug binding and preventing ER stress; ISG20L2 can additionally compete with PSMB5 for bortezomib; beyond proteolysis, PSMB5-mediated degradation of Drp1 suppresses mitochondrial fission, and PSMB5 activity modulates ROS levels, NLRP3 inflammasome activation, Hobit-driven T cell differentiation, and Nmnat2/SIRT6/NF-κB signaling in cardiac hypertrophy.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PSMB5 encodes the β5 catalytic subunit of the 20S proteasome, responsible for the chymotrypsin-like peptidase activity essential for ubiquitin-dependent protein degradation [PMID:9312091]. The active-site pocket of PSMB5 is the direct pharmacological target of bortezomib and related proteasome inhibitors; point mutations at Ala49 and Ala50 within this pocket, as well as PSMB5 gene amplification and overexpression, confer graded resistance to these drugs by reducing inhibitor binding and preventing accumulation of polyubiquitinated proteins and ER stress [PMID:18565852, PMID:19426847, PMID:20555361, PMID:22235146]. PSMB5 transcription is regulated by Nrf2-ARE, STAT3, THAP1, TGF-β/Smad3, and BRD2 (modulated by succinylation), while miR-142-3p post-transcriptionally represses PSMB5 translation [PMID:16723119, PMID:24627483, PMID:39929834, PMID:28807746, PMID:39037181, PMID:32866906]. Beyond bulk proteolysis, PSMB5-dependent proteasomal activity controls mitochondrial dynamics through Drp1 degradation, regulates replicative senescence via Cyclin D1/CDK4, and modulates CD4+ tissue-resident memory T cell differentiation by governing Hobit protein stability [PMID:30762899, PMID:24393841, PMID:39037181].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Identifying which proteasome subunit carries the chymotrypsin-like catalytic activity established PSMB5 as a core catalytic component of the 20S proteasome, answering the fundamental question of subunit–activity assignment.\",\n      \"evidence\": \"Radiolabeled active-site-directed inhibitor covalent labeling of purified 20S and 26S proteasomes with 2D-PAGE resolution and subunit-specific immunoblotting\",\n      \"pmids\": [\"9312091\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure of the human β5 active site was available at this time\", \"Relative contribution of β5 versus immunoproteasome subunit LMP7 to cellular proteolysis not quantified\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrating that IFN-γ induces replacement of constitutive PSMB5 by LMP7 (PSMB8) in the 20S proteasome explained how immunoproteasome assembly alters peptide repertoire for MHC class I presentation.\",\n      \"evidence\": \"Comparative gene structure analysis and IFN-γ stimulation studies of mouse Psmb5 vs. Psmb8 expression\",\n      \"pmids\": [\"9382924\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Subunit exchange kinetics not directly measured\", \"Functional cleavage specificity changes inferred rather than demonstrated biochemically in this study\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identifying Nrf2-ARE as a direct transcriptional regulator of PSMB5 established the first signaling axis controlling proteasome subunit expression in response to oxidative stress.\",\n      \"evidence\": \"Promoter-reporter mutagenesis of ARE elements combined with Nrf2 knockout cells\",\n      \"pmids\": [\"16723119\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Nrf2 coordinately regulates other proteasome subunits was not addressed\", \"In vivo relevance of Nrf2-driven PSMB5 induction not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Discovery that an Ala49Thr mutation in PSMB5 and PSMB5 overexpression independently confer bortezomib resistance proved that PSMB5 is the direct molecular target of this proteasome inhibitor and defined two distinct resistance mechanisms.\",\n      \"evidence\": \"Drug-resistance selection in leukemia/lymphoma cell lines, sequencing, siRNA rescue of sensitivity, gene amplification (FISH), and chymotrypsin-like activity assays\",\n      \"pmids\": [\"18565852\", \"18562081\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Clinical prevalence of PSMB5 mutations in patient-derived resistant samples not established\", \"Structural basis for reduced drug binding inferred but not crystallographically resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"A graded mutational series at Ala49/Ala50 generating 22- to 67-fold resistance quantified how progressive alteration of the binding pocket tunes drug–target interaction and chymotrypsin-like activity.\",\n      \"evidence\": \"Multiple independent resistant clones with distinct PSMB5 point mutations, fluorogenic proteasome activity assays\",\n      \"pmids\": [\"19426847\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding affinity changes not directly measured by biophysical methods\", \"Impact on non-chymotrypsin-like activities not assessed\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showing that PSMB5 Ala49Thr mutation prevents polyubiquitinated protein accumulation and catastrophic ER stress connected the resistance mechanism to specific downstream proteotoxic consequences of proteasome inhibition.\",\n      \"evidence\": \"Transfection of mutant vs. wild-type PSMB5 into parental myeloma cells with readouts for ubiquitinated protein accumulation, CHOP, and caspase activation\",\n      \"pmids\": [\"20555361\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ER stress attenuation is solely due to restored chymotrypsin-like activity or involves additional compensatory mechanisms was not resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrating cross-resistance of PSMB5 mutant cells to second-generation inhibitors (carfilzomib, ONX0912, ONX0914) unified the pharmacological target across the drug class while distinguishing PSMB5-dependent from Pgp-dependent resistance.\",\n      \"evidence\": \"Comparative resistance profiling in isogenic cell lines with PSMB5 mutations vs. Pgp-overexpressing cells\",\n      \"pmids\": [\"22235146\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding mode differences between inhibitors at the mutant pocket not structurally resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of STAT3 as a second transcriptional activator of PSMB5, synergizing with bortezomib inhibition, expanded the regulatory network governing proteasome capacity and revealed a therapeutic vulnerability.\",\n      \"evidence\": \"STAT3 gain/loss-of-function with PSMB5 promoter-luciferase, proteasome activity, and apoptosis readouts\",\n      \"pmids\": [\"24627483\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether STAT3 and Nrf2 cooperate or act independently at the PSMB5 promoter was not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Reciprocal overexpression and knockdown of PSMB5 in bone marrow stromal cells established that PSMB5-dependent proteasome activity controls replicative senescence through Cyclin D1/CDK4, extending its role beyond proteolysis to cell fate regulation.\",\n      \"evidence\": \"PSMB5 overexpression/siRNA with proteasome activity, proliferation, Cyclin D1/CDK4 Western blot, and oxidative stress challenge\",\n      \"pmids\": [\"24393841\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Cyclin D1 is a direct proteasomal substrate in this context was not shown\", \"In vivo senescence reversal not demonstrated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identification of TGF-β/Smad3 as a direct PSMB5 transcriptional regulator (via Smad binding element occupancy) added a third signaling axis and revealed tissue-specific modulation of proteasome expression.\",\n      \"evidence\": \"EMSA demonstrating Smad3 binding to Psmb5 promoter SBE, luciferase reporter, TGF-β receptor inhibitor in transgenic mice\",\n      \"pmids\": [\"28807746\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of Smad3 vs. Nrf2 vs. STAT3 to basal PSMB5 levels not quantified\", \"Tissue-specific differences in regulation not fully dissected\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrating that Nrf2-induced PSMB5 promotes Drp1 degradation and suppresses mitochondrial fission linked proteasome catalytic output to mitochondrial dynamics, establishing a non-canonical PSMB5-dependent cellular function.\",\n      \"evidence\": \"PSMB5 overexpression, Nrf2 siRNA, epoxomicin treatment, Drp1 Western blot, and mitochondrial morphology imaging\",\n      \"pmids\": [\"30762899\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ubiquitination of Drp1 by specific E3 ligase upstream of PSMB5 not identified\", \"Whether β5 activity is uniquely required or other proteasome activities contribute was not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Discovery that miR-142-3p directly represses PSMB5 translation established the first post-transcriptional regulatory mechanism for this subunit, linking p300 histone acetyltransferase activity to proteasome capacity.\",\n      \"evidence\": \"miR-142-3p overexpression/inhibition, PSMB5 3′UTR luciferase reporter, p300 activity assay, in vivo xenograft\",\n      \"pmids\": [\"32866906\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether miR-142-3p targets other proteasome subunits was not tested\", \"Endogenous miR-142-3p levels in relevant disease contexts not characterized\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placing PSMB5 downstream of CXCR4 signaling for HMGB1-induced Drp1 proteolysis in endothelial cells demonstrated receptor-to-proteasome signal transduction controlling mitochondrial fusion independently of NRF2.\",\n      \"evidence\": \"Pharmacological epistasis (AMD3100, epoxomicin, NRF2 siRNA) with Drp1 Western blot and confocal/TEM mitochondrial imaging\",\n      \"pmids\": [\"34394840\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How CXCR4 signaling activates or upregulates PSMB5 activity mechanistically was not determined\", \"Single lab, pharmacological inhibitors only\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identification of ISG20L2 as a competitor for bortezomib binding at PSMB5 revealed a non-mutational drug-sequestration resistance mechanism, expanding the pharmacological landscape beyond target mutation and overexpression.\",\n      \"evidence\": \"Biotinylated bortezomib pull-down, surface plasmon resonance for direct binding, functional proteasome activity assays\",\n      \"pmids\": [\"36040812\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of ISG20L2–bortezomib interaction not resolved\", \"Clinical relevance of ISG20L2 expression levels in patient resistance not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrating that mitochondrial succinyl-CoA drives BRD2 succinylation to repress PSMB5 transcription, thereby stabilizing Hobit and promoting CD4+ tissue-resident memory T cell differentiation, connected metabolic reprogramming to adaptive immune cell fate via proteasome regulation.\",\n      \"evidence\": \"ChIP-qPCR of BRD2 at PSMB5 promoter, PSMB5 knockdown, succinyl-CoA manipulation in T cells, humanized NSG chimera model\",\n      \"pmids\": [\"39037181\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Hobit is a direct proteasomal substrate was not formally shown\", \"Generalizability beyond RA T cells not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identification of THAP1 as an essential transcriptional regulator of PSMB5 — with PSMB5 rescue fully reversing THAP1-loss toxicity — placed THAP1 as a master upstream regulator and linked THAP1-associated dystonia biology to proteasome biogenesis.\",\n      \"evidence\": \"Genome-wide coessentiality screen, THAP1 knockout/knockdown with PSMB5 rescue, RNA-seq, ubiquitinated protein accumulation, deep mutational scanning\",\n      \"pmids\": [\"39929834\", \"39952963\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether THAP1 binds the PSMB5 promoter directly (ChIP) was not shown in this study\", \"Whether other THAP1-regulated proteasome subunits contribute to the phenotype remains open\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A complete structural and quantitative understanding of how multiple transcription factors (Nrf2, STAT3, THAP1, Smad3, BRD2) integrate at the PSMB5 promoter to set proteasome capacity in different cell types, and how PSMB5 activity selects specific substrates (e.g., Drp1, Hobit, Cyclin D1) for degradation, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No integrative promoter occupancy model across all five known transcription factors\", \"Substrate specificity determinants for PSMB5-dependent degradation of Drp1, Hobit, and Cyclin D1 are unknown\", \"Clinical frequency of PSMB5 mutations or ISG20L2-mediated resistance in bortezomib-treated patients remains poorly defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [3, 2, 5]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3, 11, 14, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [3, 0, 1, 2, 11]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 17]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [7, 14]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 5, 9]}\n    ],\n    \"complexes\": [\n      \"20S proteasome\"\n    ],\n    \"partners\": [\n      \"LMP7\",\n      \"ISG20L2\",\n      \"THAP1\",\n      \"BRD2\",\n      \"NRF2\",\n      \"STAT3\",\n      \"SMAD3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"PSMB5 encodes the β5 catalytic subunit of the 20S proteasome, harboring a threonine-based active site that provides the principal chymotrypsin-like peptidase activity of the ubiquitin–proteasome system [PMID:8811196, PMID:9312091]. Its expression is maintained basally by THAP1 and induced by Nrf2-ARE, STAT3, Gα12/13, TGF-β/Smad3, and BRD2, while miR-142-3p and miR-127-3p post-transcriptionally repress PSMB5 levels; IFN-γ triggers displacement of PSMB5 by the immunoproteasome paralog LMP7, remodeling cleavage specificity for MHC class I antigen presentation [PMID:39929834, PMID:24627483, PMID:16723119, PMID:9382924, PMID:32866906]. Bortezomib binds directly within the PSMB5 active-site pocket at residues Ala49/Ala50, and point mutations at these positions or PSMB5 overexpression confer proteasome-inhibitor resistance by reducing drug binding and preventing ER stress–mediated apoptosis, while ISG20L2 independently competes with PSMB5 for bortezomib [PMID:18565852, PMID:19426847, PMID:20555361, PMID:36040812]. Beyond bulk proteolysis, PSMB5-dependent degradation of specific substrates such as Drp1 suppresses mitochondrial fission, and altered PSMB5 activity modulates ROS-dependent NLRP3 inflammasome activation, Hobit-driven tissue-resident memory T cell differentiation, and Nmnat2/SIRT6/NF-κB signaling in cardiac hypertrophy [PMID:30762899, PMID:36061354, PMID:39037181, PMID:33315278].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Identification of PSMB5 as a catalytic subunit of the 20S proteasome with a threonine-based active site responsible for chymotrypsin-like activity resolved the longstanding question of which subunits harbor the proteolytic centers of the multicatalytic protease.\",\n      \"evidence\": \"Biochemical purification, kinetic analysis, and active-site characterization synthesized across multiple labs\",\n      \"pmids\": [\"8811196\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure of human PSMB5 in the 20S context was not yet available\", \"Relative contribution of β5 versus β1/β2 to overall proteasomal flux was not quantified\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Active-site-directed inhibitor labeling confirmed that PSMB5 is one of the catalytically active subunits and established that IFN-γ-induced LMP7 displaces PSMB5, fundamentally altering proteasome cleavage specificity for immune function.\",\n      \"evidence\": \"Radiolabeled peptidyl inhibitor labeling with 2D-PAGE/HPLC of purified 20S/26S proteasomes; genomic cloning showing distinct evolutionary origin of PSMB5 vs. LMP7\",\n      \"pmids\": [\"9312091\", \"9382924\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism governing selective incorporation of LMP7 versus PSMB5 into assembling proteasomes was unresolved\", \"In vivo antigen repertoire consequences of β5↔LMP7 exchange not directly measured\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Discovery that Nrf2-ARE elements in the PSMB5 promoter mediate stress-responsive transcriptional induction established the first defined pathway linking oxidative stress sensing to proteasome subunit upregulation.\",\n      \"evidence\": \"Promoter-reporter mutagenesis of AREs plus validation in nrf2-null cells\",\n      \"pmids\": [\"16723119\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Nrf2 coordinately induces all catalytic β subunits or selectively PSMB5 was unclear\", \"Physiological stimuli beyond 3-methylcholanthrene activating this axis were not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of the Ala49Thr mutation in the bortezomib-binding pocket of PSMB5 — combined with up to 60-fold PSMB5 overexpression — as the molecular basis of acquired bortezomib resistance resolved a critical question for proteasome inhibitor pharmacology.\",\n      \"evidence\": \"DNA sequencing, siRNA rescue of sensitivity, and chymotrypsin-like activity assay in THP1 and Jurkat resistant lines; FISH-confirmed gene amplification\",\n      \"pmids\": [\"18565852\", \"18562081\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PSMB5 mutations occur in clinical bortezomib-refractory patients at appreciable frequency was unknown\", \"Structural basis of how Ala49 mutations alter the binding pocket was modeled but not crystallographically resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Systematic mutagenesis at Ala49 and Ala50 established a quantitative structure–resistance relationship, demonstrating that both residues form the critical bortezomib-docking contacts and that double mutations confer >60-fold resistance.\",\n      \"evidence\": \"Multiple independent PSMB5 point mutations (Ala49Thr, Ala49Val, Ala49Thr+Ala50Val) with graded cytotoxicity and activity data in Jurkat clones\",\n      \"pmids\": [\"19426847\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cross-resistance profile to next-generation inhibitors had not yet been evaluated\", \"Impact of these mutations on substrate specificity beyond drug binding was not assessed\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"The mechanistic link between PSMB5 mutations and drug resistance was completed by showing that mutant PSMB5 prevents bortezomib-induced accumulation of polyubiquitinated proteins and catastrophic ER stress/CHOP induction, while Gα12/13 signaling was identified as an upstream transcriptional regulator of PSMB5.\",\n      \"evidence\": \"Transfection of mutant vs. wild-type PSMB5 with ER stress readouts; bidirectional Gα12/13 manipulation with proteasome activity assays\",\n      \"pmids\": [\"20555361\", \"20478922\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Gα12/13 acts through Nrf2, STAT3, or an independent transcription factor on the PSMB5 promoter was unresolved\", \"In vivo relevance of Gα12/13-PSMB5 axis in tumor drug response was untested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"PSMB5 mutations were shown to confer cross-resistance to carfilzomib and related next-generation proteasome inhibitors, indicating the binding pocket alterations are not bortezomib-specific; P-glycoprotein overexpression was identified as an independent co-resistance mechanism.\",\n      \"evidence\": \"Multi-inhibitor cytotoxicity and activity assays with Pgp inhibitor reversal in THP1 resistant sublines\",\n      \"pmids\": [\"22235146\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative clinical prevalence of PSMB5 mutation versus Pgp-mediated resistance was unknown\", \"Whether newer epoxyketone inhibitors fully bypass Ala49/50 mutations required structural studies\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"STAT3 was established as a direct transcriptional activator of PSMB5 via the EGF-EGFR axis, adding a growth-factor-driven regulatory input, while PSMB5 overexpression was shown to restore proteasome activity and proliferation in senescent stromal cells via Cyclin D1/CDK4.\",\n      \"evidence\": \"Bidirectional STAT3 manipulation with promoter-reporter assays; PSMB5 gain/loss-of-function in senescent bone marrow stromal cells with proliferation and survival readouts\",\n      \"pmids\": [\"24627483\", \"24393841\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether STAT3 and Nrf2 act on overlapping or distinct PSMB5 promoter elements was not determined\", \"Cyclin D1 as a direct PSMB5-degraded substrate versus indirect effect was unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"TGF-β/Smad3 was shown to directly bind the PSMB5 promoter via an SBE, adding a tissue-context-dependent transcriptional input, while PSMB5 knockdown in breast cancer cells inhibited growth, migration, and M2 macrophage polarization, broadening PSMB5's biological roles beyond proteolysis per se.\",\n      \"evidence\": \"EMSA for Smad3-SBE binding plus TGF-βRI inhibitor; shRNA in MDA-MB-231 with in vivo tumor model and THP-1 macrophage differentiation assays\",\n      \"pmids\": [\"28807746\", \"29218236\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Substrates whose degradation mediates the M1/M2 polarization shift were not identified\", \"Tissue-specific integration of multiple transcription factors on the PSMB5 promoter lacked a unified model\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Two miRNAs — miR-127-3p and miR-142-3p — were validated as direct post-transcriptional repressors of PSMB5 via 3ʹ-UTR targeting, establishing that PSMB5 levels are tuned by both transcriptional and post-transcriptional mechanisms; PSMB5-mediated degradation of Drp1 was identified as a specific substrate-level mechanism suppressing mitochondrial fission.\",\n      \"evidence\": \"3ʹ-UTR luciferase reporters for both miRNAs; CTCF-miR-127-3p axis in prostate cancer; Nrf2 siRNA plus epoxomicin blockade confirming PSMB5→Drp1 degradation in endothelial cells\",\n      \"pmids\": [\"31562641\", \"32866906\", \"30762899\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Drp1 is directly ubiquitinated for PSMB5-mediated degradation or indirectly stabilized was unresolved\", \"Quantitative impact of miRNA regulation on steady-state proteasome pools in vivo was not measured\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"PSMB5 was positioned upstream of an Nmnat2→SIRT6→NF-κB cardioprotective axis, and an HMGB1/CXCR4 pathway was shown to signal through PSMB5 to degrade Drp1 independently of Nrf2, expanding the upstream receptor inputs that converge on PSMB5-dependent proteostasis.\",\n      \"evidence\": \"PSMB5 knockdown attenuating EGCG anti-hypertrophic effects with NF-κB EMSA/reporter; receptor-specific inhibitors (AMD3100) and epoxomicin dissecting HMGB1→CXCR4→PSMB5→Drp1 axis\",\n      \"pmids\": [\"33315278\", \"34394840\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct physical interaction between CXCR4 signaling intermediates and PSMB5 promoter elements was not demonstrated\", \"Whether PSMB5 directly stabilizes Nmnat2 or prevents its degradation was ambiguous\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"ISG20L2 was identified as a direct competitor of PSMB5 for bortezomib binding, revealing a novel resistance mechanism independent of PSMB5 mutation; simultaneously, PSMB5 overexpression was shown to suppress NLRP3 inflammasome activation via ROS reduction, and reduced PSMB5 expression was linked to CGG repeat-associated neurodegeneration in FXTAS models.\",\n      \"evidence\": \"Biotinylated bortezomib pull-down plus SPR for ISG20L2; PSMB5 overexpression with NLRP3/ROS readouts in DSS colitis model; cross-species PSMB5 knockdown in Drosophila FXTAS plus human eQTL association\",\n      \"pmids\": [\"36040812\", \"36061354\", \"35617426\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of ISG20L2-bortezomib interaction was not resolved\", \"Whether PSMB5's ROS-modulating effect is direct or secondary to altered proteostasis was unclear\", \"Mechanism by which reduced PSMB5 alleviates CGG repeat toxicity (RAN translation vs. RNA-mediated) was not fully disentangled\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"BRD2 was identified as a direct transcriptional activator of PSMB5 by ChIP-qPCR, and metabolic succinylation of BRD2 in rheumatoid arthritis T cells impairs PSMB5 transcription, leading to Hobit accumulation and tissue-resident memory T cell differentiation — linking proteasome dysfunction to autoimmune pathology.\",\n      \"evidence\": \"BRD2 ChIP-qPCR at PSMB5 promoter, succinyl-CoA manipulation, Hobit knockdown rescue, humanized NSG chimera model\",\n      \"pmids\": [\"39037181\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Hobit is a direct PSMB5 degradation substrate or accumulates indirectly was not established\", \"Generalizability of succinylation-BRD2-PSMB5 axis beyond RA T cells was untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Two independent studies established THAP1 as the critical basal transcriptional regulator of PSMB5, demonstrating that THAP1 loss reduces PSMB5 expression, disrupts proteasome assembly, impairs proteostasis, and causes cell death — rescued by exogenous PSMB5 — implicating proteasome dysfunction in DYT6 dystonia pathogenesis.\",\n      \"evidence\": \"Genome-wide CRISPR coessentiality screen, THAP1 knockout with PSMB5 rescue, proteasome assembly assays, deep mutational scan of THAP1 variants correlated with PSMB5 regulatory capacity\",\n      \"pmids\": [\"39929834\", \"39952963\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct THAP1 binding site(s) on the PSMB5 promoter were not mapped at base-pair resolution in these studies\", \"Whether THAP1-PSMB5 dysregulation is the primary driver of DYT6 neurodegeneration versus other THAP1 targets requires further dissection\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A unified model integrating how multiple transcription factors (THAP1, Nrf2, STAT3, Smad3, BRD2, Gα12/13) and post-transcriptional regulators (miR-142-3p, miR-127-3p) are hierarchically organized on the PSMB5 promoter under different physiological and stress conditions remains to be established, along with systematic identification of PSMB5-specific degradation substrates beyond Drp1 and Hobit.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No integrated promoter occupancy map combining all known PSMB5 transcriptional regulators exists\", \"Systematic substrate profiling (e.g., TAILS or ubiquitin-remnant proteomics) for PSMB5-specific cleavage has not been performed\", \"Whether PSMB5 mutations in drug-resistant tumors occur at clinically meaningful frequencies remains unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 1, 11, 15, 18]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 21, 22]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 5, 6, 7, 9, 20]}\n    ],\n    \"complexes\": [\n      \"20S proteasome\",\n      \"26S proteasome\"\n    ],\n    \"partners\": [\n      \"LMP7\",\n      \"ISG20L2\",\n      \"THAP1\",\n      \"STAT3\",\n      \"BRD2\",\n      \"DRP1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}